BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Forner A, Ayuso C, Varela M, Rimola J, Hessheimer AJ, de Lope CR, Reig M, Bianchi L, Llovet JM, Bruix J. Evaluation of tumor response after locoregional therapies in hepatocellular carcinoma: are response evaluation criteria in solid tumors reliable? Cancer. 2009;115:616-623. [PMID: 19117042 DOI: 10.1002/cncr.24050] [Cited by in Crossref: 303] [Cited by in F6Publishing: 267] [Article Influence: 25.3] [Reference Citation Analysis]
Number Citing Articles
1 Georgiades C, Geschwind JF, Harrison N, Hines-Peralta A, Liapi E, Hong K, Wu Z, Kamel I, Frangakis C. Lack of response after initial chemoembolization for hepatocellular carcinoma: does it predict failure of subsequent treatment? Radiology 2012;265:115-23. [PMID: 22891361 DOI: 10.1148/radiol.12112264] [Cited by in Crossref: 72] [Cited by in F6Publishing: 60] [Article Influence: 8.0] [Reference Citation Analysis]
2 Wo JY, Dawson LA, Zhu AX, Hong TS. An emerging role for radiation therapy in the treatment of hepatocellular carcinoma and intrahepatic cholangiocarcinoma. Surg Oncol Clin N Am. 2014;23:353-368. [PMID: 24560114 DOI: 10.1016/j.soc.2013.10.007] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
3 Aykan NF, Özatlı T. Objective response rate assessment in oncology: Current situation and future expectations. World J Clin Oncol 2020;11:53-73. [PMID: 32133275 DOI: 10.5306/wjco.v11.i2.53] [Cited by in CrossRef: 12] [Cited by in F6Publishing: 8] [Article Influence: 12.0] [Reference Citation Analysis]
4 European Association for Study of Liver. European Organisation for Research and Treatment of Cancer. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. Eur J Cancer. 2012;48:599-641. [PMID: 22424278 DOI: 10.1016/j.ejca.2011.12.021] [Cited by in Crossref: 273] [Cited by in F6Publishing: 243] [Article Influence: 30.3] [Reference Citation Analysis]
5 Hyder O, Marsh JW, Salem R, Petre EN, Kalva S, Liapi E, Cosgrove D, Neal D, Kamel I, Zhu AX, Sofocleous CT, Geschwind JF, Pawlik TM. Intra-arterial therapy for advanced intrahepatic cholangiocarcinoma: a multi-institutional analysis. Ann Surg Oncol. 2013;20:3779-3786. [PMID: 23846786 DOI: 10.1245/s10434-013-3127-y] [Cited by in Crossref: 74] [Cited by in F6Publishing: 61] [Article Influence: 9.3] [Reference Citation Analysis]
6 Hu HT, Kim JH, Lee LS, Kim KA, Ko GY, Yoon HK, Sung KB, Gwon DI, Shin JH, Song HY. Chemoembolization for hepatocellular carcinoma: multivariate analysis of predicting factors for tumor response and survival in a 362-patient cohort. J Vasc Interv Radiol. 2011;22:917-923. [PMID: 21571545 DOI: 10.1016/j.jvir.2011.03.005] [Cited by in Crossref: 60] [Cited by in F6Publishing: 51] [Article Influence: 6.0] [Reference Citation Analysis]
7 Hernández-Breijo B, Monserrat J, Ramírez-Rubio S, Cuevas EP, Vara D, Díaz-Laviada I, Fernández-Moreno MD, Román ID, Gisbert JP, Guijarro LG. Preclinical evaluation of azathioprine plus buthionine sulfoximine in the treatment of human hepatocarcinoma and colon carcinoma. World J Gastroenterol. 2011;17:3899-3911. [PMID: 22025878 DOI: 10.3748/wjg.v17.i34.3899] [Cited by in CrossRef: 20] [Cited by in F6Publishing: 18] [Article Influence: 2.2] [Reference Citation Analysis]
8 Kokabi N, Camacho JC, Xing M, Edalat F, Mittal PK, Kim HS. Immediate post-doxorubicin drug-eluting beads chemoembolization Mr Apparent diffusion coefficient quantification predicts response in unresectable hepatocellular carcinoma: A pilot study. J Magn Reson Imaging. 2015;42:981-989. [PMID: 25683022 DOI: 10.1002/jmri.24845] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 3.0] [Reference Citation Analysis]
9 Stroehl YW, Letzen BS, van Breugel JM, Geschwind JF, Chapiro J. Intra-arterial therapies for liver cancer: assessing tumor response. Expert Rev Anticancer Ther 2017;17:119-27. [PMID: 27983883 DOI: 10.1080/14737140.2017.1273775] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.6] [Reference Citation Analysis]
10 Janoray G, Barillot I, Calais G. [Evaluation of the therapeutic response after stereotactic body radiation therapy for liver tumors]. Cancer Radiother 2014;18:320-4. [PMID: 24811896 DOI: 10.1016/j.canrad.2014.02.007] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
11 Gade TPF, Tucker E, Nakazawa MS, Hunt SJ, Wong W, Krock B, Weber CN, Nadolski GJ, Clark TWI, Soulen MC, Furth EE, Winkler JD, Amaravadi RK, Simon MC. Ischemia Induces Quiescence and Autophagy Dependence in Hepatocellular Carcinoma. Radiology 2017;283:702-10. [PMID: 28253108 DOI: 10.1148/radiol.2017160728] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 6.0] [Reference Citation Analysis]
12 Bonekamp S, Jolepalem P, Lazo M, Gulsun MA, Kiraly AP, Kamel IR. Hepatocellular carcinoma: response to TACE assessed with semiautomated volumetric and functional analysis of diffusion-weighted and contrast-enhanced MR imaging data. Radiology. 2011;260:752-761. [PMID: 21771960 DOI: 10.1148/radiol.11102330] [Cited by in Crossref: 79] [Cited by in F6Publishing: 65] [Article Influence: 7.9] [Reference Citation Analysis]
13 Galle PR, Tovoli F, Foerster F, Wörns MA, Cucchetti A, Bolondi L. The treatment of intermediate stage tumours beyond TACE: From surgery to systemic therapy. Journal of Hepatology 2017;67:173-83. [DOI: 10.1016/j.jhep.2017.03.007] [Cited by in Crossref: 69] [Cited by in F6Publishing: 63] [Article Influence: 17.3] [Reference Citation Analysis]
14 Jiang HY, Chen J, Xia CC, Cao LK, Duan T, Song B. Noninvasive imaging of hepatocellular carcinoma: From diagnosis to prognosis. World J Gastroenterol. 2018;24:2348-2362. [PMID: 29904242 DOI: 10.3748/wjg.v24.i22.2348] [Cited by in CrossRef: 41] [Cited by in F6Publishing: 30] [Article Influence: 13.7] [Reference Citation Analysis]
15 European Association For The Study Of The Liver. European Organisation For Research And Treatment Of Cancer. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2012;56:908-943. [PMID: 22424438 DOI: 10.1016/j.jhep.2011.12.001] [Cited by in Crossref: 3642] [Cited by in F6Publishing: 3102] [Article Influence: 404.7] [Reference Citation Analysis]
16 Raoul JL, Adhoute X, Gilabert M, Edeline J. How to assess the efficacy or failure of targeted therapy: Deciding when to stop sorafenib in hepatocellular carcinoma. World J Hepatol. 2016;8:1541-1546. [PMID: 28050234 DOI: 10.4254/wjh.v8.i35.1541] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.4] [Reference Citation Analysis]
17 Adhoute X, Penaranda G, Castellani P, Perrier H, Bourliere M. Recommendations for the use of chemoembolization in patients with hepatocellular carcinoma: Usefulness of scoring system? World J Hepatol. 2015;7:521-531. [PMID: 25848475 DOI: 10.4254/wjh.v7.i3.521] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
18 Mehrabian H, Chandrana C, Pang I, Chopra R, Martel AL. Arterial input function calculation in dynamic contrast-enhanced MRI: an in vivo validation study using co-registered contrast-enhanced ultrasound imaging. Eur Radiol 2012;22:1735-47. [DOI: 10.1007/s00330-012-2418-1] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
19 Bapst B, Lagadec M, Breguet R, Vilgrain V, Ronot M. Cone Beam Computed Tomography (CBCT) in the Field of Interventional Oncology of the Liver. Cardiovasc Intervent Radiol 2016;39:8-20. [DOI: 10.1007/s00270-015-1180-6] [Cited by in Crossref: 42] [Cited by in F6Publishing: 24] [Article Influence: 7.0] [Reference Citation Analysis]
20 Guo Y, Yaghmai V, Salem R, Lewandowski RJ, Nikolaidis P, Larson AC, Miller FH. Imaging tumor response following liver-directed intra-arterial therapy. Abdom Imaging. 2013;38:1286-1299. [PMID: 23807705 DOI: 10.1007/s00261-013-0017-5] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 3.0] [Reference Citation Analysis]
21 Shim JH, Lee HC, Kim SO, Shin YM, Kim KM, Lim YS, Suh DJ. Which response criteria best help predict survival of patients with hepatocellular carcinoma following chemoembolization? A validation study of old and new models. Radiology. 2012;262:708-718. [PMID: 22187634 DOI: 10.1148/radiol.11110282] [Cited by in Crossref: 186] [Cited by in F6Publishing: 157] [Article Influence: 18.6] [Reference Citation Analysis]
22 Lin M, Pellerin O, Bhagat N, Rao PP, Loffroy R, Ardon R, Mory B, Reyes DK, Geschwind JF. Quantitative and volumetric European Association for the Study of the Liver and Response Evaluation Criteria in Solid Tumors measurements: feasibility of a semiautomated software method to assess tumor response after transcatheter arterial chemoembolization. J Vasc Interv Radiol. 2012;23:1629-1637. [PMID: 23177109 DOI: 10.1016/j.jvir.2012.08.028] [Cited by in Crossref: 68] [Cited by in F6Publishing: 60] [Article Influence: 8.5] [Reference Citation Analysis]
23 Palner M, Shen B, Jeon J, Lin J, Chin FT, Rao J. Preclinical Kinetic Analysis of the Caspase-3/7 PET Tracer 18F-C-SNAT: Quantifying the Changes in Blood Flow and Tumor Retention After Chemotherapy. J Nucl Med 2015;56:1415-21. [PMID: 26045308 DOI: 10.2967/jnumed.115.155259] [Cited by in Crossref: 37] [Cited by in F6Publishing: 26] [Article Influence: 6.2] [Reference Citation Analysis]
24 Malagari K, Pomoni M, Kelekis A, Pomoni A, Dourakis S, Spyridopoulos T, Moschouris H, Emmanouil E, Rizos S, Kelekis D. Prospective Randomized Comparison of Chemoembolization with Doxorubicin-Eluting Beads and Bland Embolization with BeadBlock for Hepatocellular Carcinoma. Cardiovasc Intervent Radiol 2010;33:541-51. [DOI: 10.1007/s00270-009-9750-0] [Cited by in Crossref: 239] [Cited by in F6Publishing: 195] [Article Influence: 19.9] [Reference Citation Analysis]
25 Gregory J, Dioguardi Burgio M, Corrias G, Vilgrain V, Ronot M. Evaluation of liver tumour response by imaging. JHEP Rep 2020;2:100100. [PMID: 32514496 DOI: 10.1016/j.jhepr.2020.100100] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 9.0] [Reference Citation Analysis]
26 Ahmed M, Solbiati L, Brace CL, Breen DJ, Callstrom MR, Charboneau JW, Chen MH, Choi BI, de Baère T, Dodd GD. Image-guided tumor ablation: standardization of terminology and reporting criteria--a 10-year update. J Vasc Interv Radiol. 2014;25:1691-705.e4. [PMID: 25442132 DOI: 10.1016/j.jvir.2014.08.027] [Cited by in Crossref: 253] [Cited by in F6Publishing: 189] [Article Influence: 36.1] [Reference Citation Analysis]
27 Saeed M, Wilson M. Value of MR contrast media in image-guided body interventions. World J Radiol. 2012;4:1-12. [PMID: 22328966 DOI: 10.4329/wjr.v4.i1.1] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
28 Schiffman SC, Metzger T, Dubel G, Andrasina T, Kralj I, Tatum C, McMasters KM, Scoggins CR, Martin RC. Precision hepatic arterial irinotecan therapy in the treatment of unresectable intrahepatic cholangiocellular carcinoma: optimal tolerance and prolonged overall survival. Ann Surg Oncol. 2011;18:431-438. [PMID: 20862554 DOI: 10.1245/s10434-010-1333-4] [Cited by in Crossref: 27] [Cited by in F6Publishing: 24] [Article Influence: 2.5] [Reference Citation Analysis]
29 Lencioni R, Petruzzi P, Crocetti L. Chemoembolization of hepatocellular carcinoma. Semin Intervent Radiol 2013;30:3-11. [PMID: 24436512 DOI: 10.1055/s-0033-1333648] [Cited by in Crossref: 97] [Cited by in F6Publishing: 69] [Article Influence: 13.9] [Reference Citation Analysis]
30 Guo Y, Zhang Y, Nijm GM, Sahakian AV, Yang GY, Omary RA, Larson AC. Irreversible electroporation in the liver: contrast-enhanced inversion-recovery MR imaging approaches to differentiate reversibly electroporated penumbra from irreversibly electroporated ablation zones. Radiology 2011;258:461-8. [PMID: 21131581 DOI: 10.1148/radiol.10100645] [Cited by in Crossref: 51] [Cited by in F6Publishing: 35] [Article Influence: 4.6] [Reference Citation Analysis]
31 Donati OF, Do RK, Hötker AM, Katz SS, Zheng J, Moskowitz CS, Beattie C, Brown KT. Interreader and inter-test agreement in assessing treatment response following transarterial embolization for hepatocellular carcinoma. Eur Radiol 2015;25:2779-88. [PMID: 25850892 DOI: 10.1007/s00330-015-3677-4] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
32 Mahnken AH. [Transarterial ablative therapy of hepatocellular carcinoma]. Radiologe 2014;54:685-93. [PMID: 25047524 DOI: 10.1007/s00117-014-2655-1] [Reference Citation Analysis]
33 Morsbach F, Sah BR, Spring L, Puippe G, Gordic S, Seifert B, Schaefer N, Pfammatter T, Alkadhi H, Reiner CS. Perfusion CT best predicts outcome after radioembolization of liver metastases: a comparison of radionuclide and CT imaging techniques. Eur Radiol 2014;24:1455-65. [PMID: 24817083 DOI: 10.1007/s00330-014-3180-3] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 2.7] [Reference Citation Analysis]
34 Garin E, Rolland Y, Edeline J, Icard N, Lenoir L, Laffont S, Mesbah H, Breton M, Sulpice L, Boudjema K, Rohou T, Raoul JL, Clement B, Boucher E. Personalized dosimetry with intensification using 90Y-loaded glass microsphere radioembolization induces prolonged overall survival in hepatocellular carcinoma patients with portal vein thrombosis. J Nucl Med. 2015;56:339-346. [PMID: 25678490 DOI: 10.2967/jnumed.114.145177] [Cited by in Crossref: 73] [Cited by in F6Publishing: 55] [Article Influence: 12.2] [Reference Citation Analysis]
35 Ranieri G, Marech I, Lorusso V, Goffredo V, Paradiso A, Ribatti D, Gadaleta CD. Molecular targeting agents associated with transarterial chemoembolization or radiofrequency ablation in hepatocarcinoma treatment. World J Gastroenterol. 2014;20:486-497. [PMID: 24574717 DOI: 10.3748/wjg.v20.i2.486] [Cited by in CrossRef: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.9] [Reference Citation Analysis]
36 Kim H, Chung JW, An S, Seong NJ, Son KR, Jae HJ, Park JH. Transarterial Chemoembolization of a Colic Branch of the Superior Mesenteric Artery in Patients with Unresectable Hepatocellular Carcinoma. Journal of Vascular and Interventional Radiology 2011;22:47-54. [DOI: 10.1016/j.jvir.2010.09.013] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
37 Salem ME, Jain N, Dyson G, Taylor S, El-Refai SM, Choi M, Shields AF, Critchfield J, Philip PA. Radiographic parameters in predicting outcome of patients with hepatocellular carcinoma treated with yttrium-90 microsphere radioembolization. ISRN Oncol 2013;2013:538376. [PMID: 24167742 DOI: 10.1155/2013/538376] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
38 Yanagawa M, Tatsumi M, Miyata H, Morii E, Tomiyama N, Watabe T, Isohashi K, Kato H, Shimosegawa E, Yamasaki M, Mori M, Doki Y, Hatazawa J. Evaluation of response to neoadjuvant chemotherapy for esophageal cancer: PET response criteria in solid tumors versus response evaluation criteria in solid tumors. J Nucl Med 2012;53:872-80. [PMID: 22582049 DOI: 10.2967/jnumed.111.098699] [Cited by in Crossref: 68] [Cited by in F6Publishing: 51] [Article Influence: 7.6] [Reference Citation Analysis]
39 Guibal A, Lefort T, Chardon L, Benslama N, Mulé S, Pilleul F, Lombard-Bohas C, Bridal L, Chayvialle JA, Lucidarme O. Contrast-enhanced ultrasound after devascularisation of neuroendocrine liver metastases: functional and morphological evaluation. Eur Radiol. 2013;23:805-815. [PMID: 23001579 DOI: 10.1007/s00330-012-2646-4] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
40 Levine ZH, Pintar AL, Hagedorn JG, Fenimore CP, Heussel CP. Uncertainties in RECIST as a measure of volume for lung nodules and liver tumors. Med Phys 2012;39:2628-37. [PMID: 22559633 DOI: 10.1118/1.3701791] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
41 Ikeda K. Recent advances in medical management of hepatocellular carcinoma. Hepatol Res. 2019;49:14-32. [PMID: 30308081 DOI: 10.1111/hepr.13259] [Cited by in Crossref: 27] [Cited by in F6Publishing: 22] [Article Influence: 9.0] [Reference Citation Analysis]
42 Xing M, Kokabi N, Camacho JC, Kooby DA, El-Rayes BF, Kim HS. 90Y radioembolization versus chemoembolization in the treatment of hepatocellular carcinoma: an analysis of comparative effectiveness. J Comp Eff Res 2013;2:435-44. [PMID: 24236684 DOI: 10.2217/cer.13.37] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
43 Pandey A, Pandey P, Aliyari Ghasabeh M, Najmi Varzaneh F, Shao N, Khoshpouri P, Zarghampour M, Fouladi DF, Liddell R, Kamel IR. Unresectable Intrahepatic Cholangiocarcinoma: Multiparametric MR Imaging to Predict Patient Survival. Radiology 2018;288:109-17. [DOI: 10.1148/radiol.2018171593] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 3.7] [Reference Citation Analysis]
44 Seyal AR, Gonzalez-Guindalini FD, Arslanoglu A, Harmath CB, Lewandowski RJ, Salem R, Yaghmai V. Reproducibility of mRECIST in assessing response to transarterial radioembolization therapy in hepatocellular carcinoma. Hepatology. 2015;62:1111-1121. [PMID: 25999236 DOI: 10.1002/hep.27915] [Cited by in Crossref: 38] [Cited by in F6Publishing: 29] [Article Influence: 6.3] [Reference Citation Analysis]
45 Manceau V, Palard X, Rolland Y, Pracht M, Le Sourd S, Laffont S, Boudjema K, Lievre A, Mesbah H, Haumont LA, Lenoir L, Brun V, Uguen T, Edeline J, Garin E. A MAA-based dosimetric study in patients with intrahepatic cholangiocarcinoma treated with a combination of chemotherapy and 90Y-loaded glass microsphere selective internal radiation therapy. Eur J Nucl Med Mol Imaging 2018;45:1731-41. [PMID: 29560519 DOI: 10.1007/s00259-018-3990-7] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
46 Perkons NR, Johnson O, Pilla G, Profka E, Mercadante M, Ackerman D, Gade TPF. Functional Genetic Screening Enables Theranostic Molecular Imaging in Cancer. Clin Cancer Res 2020;26:4581-9. [PMID: 32499234 DOI: 10.1158/1078-0432.CCR-20-0826] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
47 Raoul JL, Forner A, Bolondi L, Cheung TT, Kloeckner R, de Baere T. Updated use of TACE for hepatocellular carcinoma treatment: How and when to use it based on clinical evidence. Cancer Treat Rev 2019;72:28-36. [PMID: 30447470 DOI: 10.1016/j.ctrv.2018.11.002] [Cited by in Crossref: 72] [Cited by in F6Publishing: 60] [Article Influence: 24.0] [Reference Citation Analysis]
48 Koh DM, Ba-Ssalamah A, Brancatelli G, Fananapazir G, Fiel MI, Goshima S, Ju SH, Kartalis N, Kudo M, Lee JM, Murakami T, Seidensticker M, Sirlin CB, Tan CH, Wang J, Yoon JH, Zeng M, Zhou J, Taouli B. Consensus report from the 9th International Forum for Liver Magnetic Resonance Imaging: applications of gadoxetic acid-enhanced imaging. Eur Radiol 2021;31:5615-28. [PMID: 33523304 DOI: 10.1007/s00330-020-07637-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
49 Gallamini A, Zwarthoed C, Borra A. Positron Emission Tomography (PET) in Oncology. Cancers (Basel). 2014;6:1821-1889. [PMID: 25268160 DOI: 10.3390/cancers6041821] [Cited by in Crossref: 146] [Cited by in F6Publishing: 91] [Article Influence: 20.9] [Reference Citation Analysis]
50 Choi SJ, Kim J, Kim HS, Park H. Parametric response mapping of dynamic CT: enhanced prediction of survival in hepatocellular carcinoma patients treated with transarterial chemoembolization. Abdom Radiol (NY) 2017;42:1871-9. [PMID: 28204855 DOI: 10.1007/s00261-017-1082-y] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
51 Lencioni R. Chemoembolization for hepatocellular carcinoma. Semin Oncol 2012;39:503-9. [PMID: 22846867 DOI: 10.1053/j.seminoncol.2012.05.004] [Cited by in Crossref: 61] [Cited by in F6Publishing: 60] [Article Influence: 6.8] [Reference Citation Analysis]
52 Wáng YX, De Baere T, Idée JM, Ballet S. Transcatheter embolization therapy in liver cancer: an update of clinical evidences. Chin J Cancer Res 2015;27:96-121. [PMID: 25937772 DOI: 10.3978/j.issn.1000-9604.2015.03.03] [Cited by in F6Publishing: 24] [Reference Citation Analysis]
53 Cools KS, Moon AM, Burke LMB, McGinty KA, Strassle PD, Gerber DA. Validation of the Liver Imaging Reporting and Data System Treatment Response Criteria After Thermal Ablation for Hepatocellular Carcinoma. Liver Transpl 2020;26:203-14. [PMID: 31677319 DOI: 10.1002/lt.25673] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 7.5] [Reference Citation Analysis]
54 Salem R, Lewandowski RJ. Chemoembolization and radioembolization for hepatocellular carcinoma. Clin Gastroenterol Hepatol. 2013;11:604-11; quiz e43-44. [PMID: 23357493 DOI: 10.1016/j.cgh.2012.12.039] [Cited by in Crossref: 48] [Cited by in F6Publishing: 29] [Article Influence: 6.0] [Reference Citation Analysis]
55 Ahmed M, Solbiati L, Brace CL, Breen DJ, Callstrom MR, Charboneau JW, Chen MH, Choi BI, de Baère T, Dodd GD, Dupuy DE, Gervais DA, Gianfelice D, Gillams AR, Lee FT, Leen E, Lencioni R, Littrup PJ, Livraghi T, Lu DS, McGahan JP, Meloni MF, Nikolic B, Pereira PL, Liang P, Rhim H, Rose SC, Salem R, Sofocleous CT, Solomon SB, Soulen MC, Tanaka M, Vogl TJ, Wood BJ, Goldberg SN; International Working Group on Image-guided Tumor Ablation; Interventional Oncology Sans Fronti res Expert Panel; Technology Assessment Committee of the Society of Interventional Radiology,; Standard of Practice Committee of the Cardiovascular and Inter. Image-guided tumor ablation: standardization of terminology and reporting criteria--a 10-year update. Radiology. 2014;273:241-260. [PMID: 24927329 DOI: 10.1148/radiol.14132958] [Cited by in Crossref: 485] [Cited by in F6Publishing: 378] [Article Influence: 69.3] [Reference Citation Analysis]
56 Lewin M, Fartoux L, Vignaud A, Arrivé L, Menu Y, Rosmorduc O. The diffusion-weighted imaging perfusion fraction f is a potential marker of sorafenib treatment in advanced hepatocellular carcinoma: a pilot study. Eur Radiol. 2011;21:281-290. [PMID: 20683597 DOI: 10.1007/s00330-010-1914-4] [Cited by in Crossref: 97] [Cited by in F6Publishing: 86] [Article Influence: 8.8] [Reference Citation Analysis]
57 Forner A, Gilabert M, Bruix J, Raoul JL. Treatment of intermediate-stage hepatocellular carcinoma. Nat Rev Clin Oncol. 2014;11:525-535. [PMID: 25091611 DOI: 10.1038/nrclinonc.2014.122] [Cited by in Crossref: 247] [Cited by in F6Publishing: 216] [Article Influence: 35.3] [Reference Citation Analysis]
58 Frampas E, Lassau N, Zappa M, Vullierme MP, Koscielny S, Vilgrain V. Advanced Hepatocellular Carcinoma: early evaluation of response to targeted therapy and prognostic value of Perfusion CT and Dynamic Contrast Enhanced-Ultrasound. Preliminary results. Eur J Radiol. 2013;82:e205-e211. [PMID: 23273822 DOI: 10.1016/j.ejrad.2012.12.004] [Cited by in Crossref: 65] [Cited by in F6Publishing: 49] [Article Influence: 7.2] [Reference Citation Analysis]
59 Tacher V, Lin M, Chao M, Gjesteby L, Bhagat N, Mahammedi A, Ardon R, Mory B, Geschwind JF. Semiautomatic volumetric tumor segmentation for hepatocellular carcinoma: comparison between C-arm cone beam computed tomography and MRI. Acad Radiol 2013;20:446-52. [PMID: 23498985 DOI: 10.1016/j.acra.2012.11.009] [Cited by in Crossref: 40] [Cited by in F6Publishing: 28] [Article Influence: 5.0] [Reference Citation Analysis]
60 Akin O, Brennan SB, Dershaw DD, Ginsberg MS, Gollub MJ, Schöder H, Panicek DM, Hricak H. Advances in oncologic imaging: Update on 5 Common Cancers. CA: A Cancer Journal for Clinicians 2012;62:364-93. [DOI: 10.3322/caac.21156] [Cited by in Crossref: 35] [Cited by in F6Publishing: 22] [Article Influence: 3.9] [Reference Citation Analysis]
61 Yao FY, Breitenstein S, Broelsch CE, Dufour JF, Sherman M. Does a patient qualify for liver transplantation after the down-staging of hepatocellular carcinoma? Liver Transpl. 2011;17 Suppl 2:S109-S116. [PMID: 21584927 DOI: 10.1002/lt.22335] [Cited by in Crossref: 36] [Cited by in F6Publishing: 39] [Article Influence: 4.0] [Reference Citation Analysis]
62 Benson AB, Geschwind J, Mulcahy MF, Rilling W, Siskin G, Wiseman G, Cunningham J, Houghton B, Ross M, Memon K, Andrews J, Fleming CJ, Herman J, Nimeiri H, Lewandowski RJ, Salem R. Radioembolisation for liver metastases: Results from a prospective 151 patient multi-institutional phase II study. European Journal of Cancer 2013;49:3122-30. [DOI: 10.1016/j.ejca.2013.05.012] [Cited by in Crossref: 55] [Cited by in F6Publishing: 40] [Article Influence: 6.9] [Reference Citation Analysis]
63 Iavarone M, Cabibbo G, Piscaglia F, Zavaglia C, Grieco A, Villa E, Cammà C, Colombo M; on behalf of the SOFIA (SOraFenib Italian Assessment) study group. Field-practice study of sorafenib therapy for hepatocellular carcinoma: A prospective multicenter study in Italy. Hepatology 2011;54:2055-63. [DOI: 10.1002/hep.24644] [Cited by in Crossref: 237] [Cited by in F6Publishing: 229] [Article Influence: 23.7] [Reference Citation Analysis]
64 Kim JH, Yoon H, Ko G, Gwon DI, Jang CS, Song H, Shin JH, Sung K. Nonresectable Combined Hepatocellular Carcinoma and Cholangiocarcinoma: Analysis of the Response and Prognostic Factors after Transcatheter Arterial Chemoembolization. Radiology 2010;255:270-7. [DOI: 10.1148/radiol.09091076] [Cited by in Crossref: 61] [Cited by in F6Publishing: 54] [Article Influence: 5.5] [Reference Citation Analysis]
65 Tacher V, Lin M, Duran R, Yarmohammadi H, Lee H, Chapiro J, Chao M, Wang Z, Frangakis C, Sohn JH. Comparison of Existing Response Criteria in Patients with Hepatocellular Carcinoma Treated with Transarterial Chemoembolization Using a 3D Quantitative Approach. Radiology. 2016;278:275-284. [PMID: 26131913 DOI: 10.1148/radiol.2015142951] [Cited by in Crossref: 51] [Cited by in F6Publishing: 45] [Article Influence: 8.5] [Reference Citation Analysis]
66 Mahmud N, Hoteit MA, Goldberg DS. Risk Factors and Center-Level Variation in Hepatocellular Carcinoma Under-Staging for Liver Transplantation. Liver Transpl 2020;26:977-88. [PMID: 32363720 DOI: 10.1002/lt.25787] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
67 Mayo SC, de Jong MC, Bloomston M, Pulitano C, Clary BM, Reddy SK, Clark Gamblin T, Celinski SA, Kooby DA, Staley CA, Stokes JB, Chu CK, Arrese D, Ferrero A, Schulick RD, Choti MA, Geschwind JF, Strub J, Bauer TW, Adams RB, Aldrighetti L, Mentha G, Capussotti L, Pawlik TM. Surgery versus intra-arterial therapy for neuroendocrine liver metastasis: a multicenter international analysis. Ann Surg Oncol 2011;18:3657-65. [PMID: 21681380 DOI: 10.1245/s10434-011-1832-y] [Cited by in Crossref: 113] [Cited by in F6Publishing: 90] [Article Influence: 11.3] [Reference Citation Analysis]
68 Monsky WL, Garza AS, Kim I, Loh S, Lin TC, Li CS, Fisher J, Sandhu P, Sidhar V, Chaudhari AJ. Treatment planning and volumetric response assessment for Yttrium-90 radioembolization: semiautomated determination of liver volume and volume of tumor necrosis in patients with hepatic malignancy. Cardiovasc Intervent Radiol. 2011;34:306-318. [PMID: 20683722 DOI: 10.1007/s00270-010-9938-3] [Cited by in Crossref: 22] [Cited by in F6Publishing: 16] [Article Influence: 2.0] [Reference Citation Analysis]
69 Memon K, Kulik L, Lewandowski RJ, Mulcahy MF, Benson AB, Ganger D, Riaz A, Gupta R, Vouche M, Gates VL, Miller FH, Omary RA, Salem R. Radioembolization for hepatocellular carcinoma with portal vein thrombosis: impact of liver function on systemic treatment options at disease progression. J Hepatol. 2013;58:73-80. [PMID: 23000237 DOI: 10.1016/j.jhep.2012.09.003] [Cited by in Crossref: 79] [Cited by in F6Publishing: 71] [Article Influence: 8.8] [Reference Citation Analysis]
70 Akinwande O, Philips P, Scoggins CR, Kelly L, Tatum C, Hahl M, McMasters KM, Martin RC. Comparison of tumor response assessment methods in patients with metastatic colorectal cancer after locoregional therapy. J Surg Oncol 2016;113:443-8. [PMID: 27060707 DOI: 10.1002/jso.24141] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 1.8] [Reference Citation Analysis]
71 Kang H, Lee HY, Lee KS, Kim JH. Imaging-based tumor treatment response evaluation: review of conventional, new, and emerging concepts. Korean J Radiol 2012;13:371-90. [PMID: 22778559 DOI: 10.3348/kjr.2012.13.4.371] [Cited by in Crossref: 53] [Cited by in F6Publishing: 39] [Article Influence: 5.9] [Reference Citation Analysis]
72 Rimola J, Davenport MS, Liu PS, Brown T, Marrero JA, Mckenna BJ, Hussain HK. Diagnostic accuracy of MRI with extracellular vs. hepatobiliary contrast material for detection of residual hepatocellular carcinoma after locoregional treatment. Abdom Radiol 2019;44:549-58. [DOI: 10.1007/s00261-018-1775-x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 2] [Article Influence: 2.3] [Reference Citation Analysis]
73 Kim SH, Kamaya A, Willmann JK. CT perfusion of the liver: principles and applications in oncology. Radiology. 2014;272:322-344. [PMID: 25058132 DOI: 10.1148/radiol.14130091] [Cited by in Crossref: 109] [Cited by in F6Publishing: 48] [Article Influence: 15.6] [Reference Citation Analysis]
74 Wahl RL, Jacene H, Kasamon Y, Lodge MA. From RECIST to PERCIST: Evolving Considerations for PET response criteria in solid tumors. J Nucl Med 2009;50 Suppl 1:122S-50S. [PMID: 19403881 DOI: 10.2967/jnumed.108.057307] [Cited by in Crossref: 2119] [Cited by in F6Publishing: 1514] [Article Influence: 176.6] [Reference Citation Analysis]
75 Yu SC, Hui JW, Hui EP, Chan SL, Lee KF, Mo F, Wong J, Ma B, Lai P, Mok T. Unresectable hepatocellular carcinoma: randomized controlled trial of transarterial ethanol ablation versus transcatheter arterial chemoembolization. Radiology. 2014;270:607-620. [PMID: 24126369 DOI: 10.1148/radiol.13130498] [Cited by in Crossref: 24] [Cited by in F6Publishing: 21] [Article Influence: 3.0] [Reference Citation Analysis]
76 Maida M, Cabibbo G, Brancatelli G, Genco C, Alessi N, Genova C, Romano P, Raineri M, Giarratano A, Midiri M. Assessment of treatment response in hepatocellular carcinoma: a review of the literature. Future Oncol. 2013;9:845-854. [PMID: 23718305 DOI: 10.2217/fon.13.33] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
77 Kim MN, Kim BK, Han K, Kim SU. Evolution from WHO to EASL and mRECIST for hepatocellular carcinoma: considerations for tumor response assessment. Expert Review of Gastroenterology & Hepatology 2014;9:335-48. [DOI: 10.1586/17474124.2015.959929] [Cited by in Crossref: 34] [Cited by in F6Publishing: 24] [Article Influence: 4.9] [Reference Citation Analysis]
78 Dioguardi Burgio M, Sartoris R, Libotean C, Zappa M, Sibert A, Vilgrain V, Ronot M. Lipiodol retention pattern after TACE for HCC is a predictor for local progression in lesions with complete response. Cancer Imaging 2019;19:75. [PMID: 31730491 DOI: 10.1186/s40644-019-0260-2] [Cited by in Crossref: 12] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
79 Gillmore R, Stuart S, Kirkwood A, Hameeduddin A, Woodward N, Burroughs AK, Meyer T. EASL and mRECIST responses are independent prognostic factors for survival in hepatocellular cancer patients treated with transarterial embolization. J Hepatol. 2011;55:1309-1316. [PMID: 21703196 DOI: 10.1016/j.jhep.2011.03.007] [Cited by in Crossref: 224] [Cited by in F6Publishing: 199] [Article Influence: 22.4] [Reference Citation Analysis]
80 Sahani DV, Hayano K, Galluzzo A, Zhu AX. Measuring Treatment Response to Systemic Therapy and Predicting Outcome in Biliary Tract Cancer: Comparing Tumor Size, Volume, Density, and Metabolism. American Journal of Roentgenology 2015;204:776-81. [DOI: 10.2214/ajr.14.13223] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
81 Najmi Varzaneh F, Pandey A, Aliyari Ghasabeh M, Shao N, Khoshpouri P, Pandey P, Zarghampour M, Fouladi D, Liddell R, Anders RA, Kamel IR. Prediction of post-TACE necrosis of hepatocellular carcinoma usingvolumetric enhancement on MRI and volumetric oil deposition on CT, with pathological correlation. Eur Radiol. 2018;28:3032-3040. [PMID: 29383518 DOI: 10.1007/s00330-017-5198-9] [Cited by in Crossref: 16] [Cited by in F6Publishing: 7] [Article Influence: 5.3] [Reference Citation Analysis]
82 Lv WF, Han JK, Cheng DL, Zhou CZ, Ni M, Lu D. CT Perfusion Imaging Can Predict Patients' Survival and Early Response to Transarterial Chemo-Lipiodol Infusion for Liver Metastases from Colorectal Cancers. Korean J Radiol 2015;16:810-20. [PMID: 26175580 DOI: 10.3348/kjr.2015.16.4.810] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 1.2] [Reference Citation Analysis]
83 Lungren MP, Towbin AJ, Roebuck DJ, Monroe EJ, Gill AE, Thakor A, Towbin RB, Cahill AM, Matthew Hawkins C. Role of interventional radiology in managing pediatric liver tumors : Part 1: Endovascular interventions. Pediatr Radiol. 2018;48:555-564. [PMID: 29362840 DOI: 10.1007/s00247-018-4068-1] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
84 Yamashige D, Kawamura Y, Kobayashi M, Shindoh J, Kobayashi Y, Okubo S, Muraishi N, Kajiwara A, Iritani S, Fujiyama S, Hosaka T, Saitoh S, Sezaki H, Akuta N, Suzuki F, Suzuki Y, Ikeda K, Arase Y, Hashimoto M, Kumada H. Potential and Clinical Significance of 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography for Evaluating Liver Cancer Response to Lenvatinib Treatment. Oncology 2021;99:169-76. [PMID: 33207358 DOI: 10.1159/000510754] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
85 Hayano K, Lee SH, Sahani DV. Imaging for assessment of treatment response in hepatocellular carcinoma: Current update. Indian J Radiol Imaging 2015;25:121-8. [PMID: 25969635 DOI: 10.4103/0971-3026.155835] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
86 Memon K, Kulik L, Lewandowski RJ, Wang E, Riaz A, Ryu RK, Sato KT, Marshall K, Gupta R, Nikolaidis P, Miller FH, Yaghmai V, Senthilnathan S, Baker T, Gates VL, Abecassis M, Benson AB 3rd, Mulcahy MF, Omary RA, Salem R. Radiographic response to locoregional therapy in hepatocellular carcinoma predicts patient survival times. Gastroenterology 2011;141:526-35, 535.e1-2. [PMID: 21664356 DOI: 10.1053/j.gastro.2011.04.054] [Cited by in Crossref: 117] [Cited by in F6Publishing: 98] [Article Influence: 11.7] [Reference Citation Analysis]
87 Floridi C, Pesapane F, Angileri SA, De Palma D, Fontana F, Caspani F, Barile A, Del Sole A, Masciocchi C, Lucignani G, Carrafiello G. Yttrium-90 radioembolization treatment for unresectable hepatocellular carcinoma: a single-centre prognostic factors analysis. Med Oncol 2017;34. [DOI: 10.1007/s12032-017-1021-3] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
88 Hollebecque A, Cattan S, Romano O, Sergent G, Mourad A, Louvet A, Dharancy S, Boleslawski E, Truant S, Pruvot FR. Safety and efficacy of sorafenib in hepatocellular carcinoma: the impact of the Child-Pugh score. Aliment Pharmacol Ther. 2011;34:1193-1201. [PMID: 21958438 DOI: 10.1111/j.1365-2036.2011.04860.x] [Cited by in Crossref: 79] [Cited by in F6Publishing: 70] [Article Influence: 7.9] [Reference Citation Analysis]
89 Bonekamp S, Li Z, Geschwind JF, Halappa VG, Corona-Villalobos CP, Reyes D, Pawlik TM, Bonekamp D, Eng J, Kamel IR. Unresectable hepatocellular carcinoma: MR imaging after intraarterial therapy. Part I. Identification and validation of volumetric functional response criteria. Radiology 2013;268:420-30. [PMID: 23616631 DOI: 10.1148/radiol.13122307] [Cited by in Crossref: 30] [Cited by in F6Publishing: 28] [Article Influence: 3.8] [Reference Citation Analysis]
90 Lee M, Baek SE, Moon J, Roh YH, Lim JS, Park MS, Kim MJ, Kim H. Dynamic contrast-enhanced MRI coupled with a subtraction technique is useful for treatment response evaluation of malignant melanoma hepatic metastasis. Oncotarget 2016;7:38513-22. [PMID: 27229529 DOI: 10.18632/oncotarget.9567] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
91 Lencioni R, Crocetti L. Local-regional treatment of hepatocellular carcinoma. Radiology. 2012;262:43-58. [PMID: 22190656 DOI: 10.1148/radiol.11110144] [Cited by in Crossref: 211] [Cited by in F6Publishing: 175] [Article Influence: 23.4] [Reference Citation Analysis]
92 Khorsandi SE, Heaton N. Contemporary strategies in the management of hepatocellular carcinoma. HPB Surg 2012;2012:154056. [PMID: 23197879 DOI: 10.1155/2012/154056] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
93 Fiorentini G, Carandina R, Sarti D, Nardella M, Zoras O, Guadagni S, Inchingolo R, Nestola M, Felicioli A, Barnes Navarro D, Munoz Gomez F, Aliberti C. Polyethylene glycol microspheres loaded with irinotecan for arterially directed embolic therapy of metastatic liver cancer. World J Gastrointest Oncol 2017;9:379-84. [PMID: 28979720 DOI: 10.4251/wjgo.v9.i9.379] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
94 Memon K, Kulik L, Lewandowski RJ, Wang E, Ryu RK, Riaz A, Nikolaidis P, Miller FH, Yaghmai V, Baker T, Abecassis M, Benson AB, Mulcahy MF, Omary RA, Salem R. Alpha-fetoprotein response correlates with EASL response and survival in solitary hepatocellular carcinoma treated with transarterial therapies: a subgroup analysis. J Hepatol. 2012;56:1112-1120. [PMID: 22245905 DOI: 10.1016/j.jhep.2011.11.020] [Cited by in Crossref: 61] [Cited by in F6Publishing: 53] [Article Influence: 6.8] [Reference Citation Analysis]
95 Martin RC, Robbins K, Tomalty D, O'Hara R, Bosnjakovic P, Padr R, Rocek M, Slauf F, Scupchenko A, Tatum C. Transarterial chemoembolisation (TACE) using irinotecan-loaded beads for the treatment of unresectable metastases to the liver in patients with colorectal cancer: an interim report. World J Surg Oncol. 2009;7:80. [PMID: 19886993 DOI: 10.1186/1477-7819-7-80] [Cited by in Crossref: 64] [Cited by in F6Publishing: 53] [Article Influence: 5.3] [Reference Citation Analysis]
96 Schobert I, Chapiro J, Pucar D, Saperstein L, Savic LJ. Fluorodeoxyglucose PET for Monitoring Response to Embolotherapy (Transarterial Chemoembolization) in Primary and Metastatic Liver Tumors. PET Clinics 2019;14:437-45. [DOI: 10.1016/j.cpet.2019.06.008] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
97 Komatsu S, Fukumoto T, Demizu Y, Miyawaki D, Terashima K, Sasaki R, Hori Y, Hishikawa Y, Ku Y, Murakami M. Clinical results and risk factors of proton and carbon ion therapy for hepatocellular carcinoma. Cancer. 2011;117:4890-4904. [PMID: 21495022 DOI: 10.1002/cncr.26134] [Cited by in Crossref: 94] [Cited by in F6Publishing: 61] [Article Influence: 9.4] [Reference Citation Analysis]
98 de Lope CR, Tremosini S, Forner A, Reig M, Bruix J. Management of HCC. Journal of Hepatology 2012;56:S75-87. [DOI: 10.1016/s0168-8278(12)60009-9] [Cited by in Crossref: 363] [Cited by in F6Publishing: 184] [Article Influence: 40.3] [Reference Citation Analysis]
99 Yu SCH, Chan SL, Lee KF, Hui JWY, Hui EP, Chu CM, Chan AW, Cheung S, Li L, Wong J, Yeo WMM. Ablative Chemoembolization for Hepatocellular Carcinoma: A Prospective Phase I Case-Control Comparison with Conventional Chemoembolization. Radiology 2018;287:340-8. [DOI: 10.1148/radiol.2017170154] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
100 Oliveri RS, Wetterslev J, Gluud C; Cochrane Hepato-Biliary Group. Transarterial (chemo)embolisation for unresectable hepatocellular carcinoma. Cochrane Database of Systematic Reviews. [DOI: 10.1002/14651858.cd004787.pub2] [Cited by in Crossref: 86] [Cited by in F6Publishing: 95] [Article Influence: 8.6] [Reference Citation Analysis]
101 Forner A, Reig M, Varela M, Burrel M, Feliu J, Briceño J, Sastre J, Martí-Bonmati L, Llovet JM, Bilbao JI, Sangro B, Pardo F, Ayuso C, Bru C, Tabernero J, Bruix J. [Diagnosis and treatment of hepatocellular carcinoma. Update consensus document from the AEEH, SEOM, SERAM, SERVEI and SETH]. Med Clin (Barc) 2016;146:511.e1-511.e22. [PMID: 26971984 DOI: 10.1016/j.medcli.2016.01.028] [Cited by in Crossref: 35] [Cited by in F6Publishing: 20] [Article Influence: 7.0] [Reference Citation Analysis]
102 Pauwels X, Azahaf M, Lassailly G, Sergent G, Buob D, Truant S, Boleslawski E, Louvet A, Gnemmi V, Canva V, Mathurin P, Pruvot F, Leteurtre E, Ernst O, Dharancy S. Drug-Eluting Beads Loaded With Doxorubicin (DEBDOX) Chemoembolisation Before Liver Transplantation for Hepatocellular Carcinoma: An Imaging/Histologic Correlation Study. Cardiovasc Intervent Radiol 2015;38:685-92. [DOI: 10.1007/s00270-014-0967-1] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 1.1] [Reference Citation Analysis]
103 Llovet JM, De Baere T, Kulik L, Haber PK, Greten TF, Meyer T, Lencioni R. Locoregional therapies in the era of molecular and immune treatments for hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol 2021;18:293-313. [PMID: 33510460 DOI: 10.1038/s41575-020-00395-0] [Cited by in Crossref: 14] [Cited by in F6Publishing: 7] [Article Influence: 14.0] [Reference Citation Analysis]
104 Facciorusso A, Licinio R, Muscatiello N, Di Leo A, Barone M. Transarterial chemoembolization: Evidences from the literature and applications in hepatocellular carcinoma patients. World J Hepatol. 2015;7:2009-2019. [PMID: 26261690 DOI: 10.4254/wjh.v7.i16.2009] [Cited by in Crossref: 46] [Cited by in F6Publishing: 44] [Article Influence: 7.7] [Reference Citation Analysis]
105 Goffredo V, Paradiso A, Ranieri G, Gadaleta CD. Yttrium-90 (90Y) in the principal radionuclide therapies: an efficacy correlation between peptide receptor radionuclide therapy, radioimmunotherapy and transarterial radioembolization therapy. Ten years of experience (1999-2009). Crit Rev Oncol Hematol 2011;80:393-410. [PMID: 21388824 DOI: 10.1016/j.critrevonc.2011.01.012] [Cited by in Crossref: 28] [Cited by in F6Publishing: 12] [Article Influence: 2.8] [Reference Citation Analysis]
106 Gordon AC, Gupta AN, Gabr A, Thornburg BG, Kulik LM, Ganger DR, Maddur H, Flamm SL, Boike JR, Moore CM, Borja-Cacho D, Christopher DA, Katariya NN, Ladner DP, Caicedo-Ramirez JC, Riaz A, Salem R, Lewandowski RJ. Safety and Efficacy of Segmental Yttrium-90 Radioembolization for Hepatocellular Carcinoma after Transjugular Intrahepatic Portosystemic Shunt Creation. J Vasc Interv Radiol 2021;32:211-9. [PMID: 33349507 DOI: 10.1016/j.jvir.2020.09.007] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
107 Perkons NR, Kiefer RM, Noji MC, Pourfathi M, Ackerman D, Siddiqui S, Tischfield D, Profka E, Johnson O, Pickup S, Mancuso A, Pantel A, Denburg MR, Nadolski GJ, Hunt SJ, Furth EE, Kadlecek S, Gade TPF. Hyperpolarized Metabolic Imaging Detects Latent Hepatocellular Carcinoma Domains Surviving Locoregional Therapy. Hepatology 2020;72:140-54. [PMID: 31553806 DOI: 10.1002/hep.30970] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
108 Liapi E, Geschwind JF. Intra-arterial therapies for hepatocellular carcinoma: where do we stand? Ann Surg Oncol. 2010;17:1234-1246. [PMID: 20405328 DOI: 10.1245/s10434-010-0977-4] [Cited by in Crossref: 55] [Cited by in F6Publishing: 41] [Article Influence: 5.0] [Reference Citation Analysis]
109 Bruix J. Endpoints in clinical trials for liver cancer and their value in evidence-based clinical decision making: An unresolved Gordian knot. J Hepatol 2021;74:1483-8. [PMID: 33556420 DOI: 10.1016/j.jhep.2021.01.033] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
110 Habib A, Desai K, Hickey R, Thornburg B, Lewandowski R, Salem R. Locoregional Therapy of Hepatocellular Carcinoma. Clinics in Liver Disease 2015;19:401-20. [DOI: 10.1016/j.cld.2015.01.008] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 2.8] [Reference Citation Analysis]
111 Takada J, Hidaka H, Nakazawa T, Kondo M, Numata K, Tanaka K, Matsunaga K, Okuse C, Kobayashi S, Morimoto M, Ohkawa S, Koizumi W. Modified response evaluation criteria in solid tumors is superior to response evaluation criteria in solid tumors for assessment of responses to sorafenib in patients with advanced hepatocellular carcinoma. BMC Res Notes 2015;8:609. [PMID: 26502722 DOI: 10.1186/s13104-015-1565-2] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 2.5] [Reference Citation Analysis]
112 Jung ES, Kim JH, Yoon EL, Lee HJ, Lee SJ, Suh SJ, Lee BJ, Seo YS, Yim HJ, Seo TS. Comparison of the methods for tumor response assessment in patients with hepatocellular carcinoma undergoing transarterial chemoembolization. J Hepatol. 2013;58:1181-1187. [PMID: 23395691 DOI: 10.1016/j.jhep.2013.01.039] [Cited by in Crossref: 82] [Cited by in F6Publishing: 72] [Article Influence: 10.3] [Reference Citation Analysis]
113 Yang JD, Roberts LR. Epidemiology and management of hepatocellular carcinoma. Infect Dis Clin North Am 2010;24:899-919, viii. [PMID: 20937457 DOI: 10.1016/j.idc.2010.07.004] [Cited by in Crossref: 120] [Cited by in F6Publishing: 93] [Article Influence: 12.0] [Reference Citation Analysis]
114 Mouli S, Memon K, Baker T, Benson AB 3rd, Mulcahy MF, Gupta R, Ryu RK, Salem R, Lewandowski RJ. Yttrium-90 radioembolization for intrahepatic cholangiocarcinoma: safety, response, and survival analysis. J Vasc Interv Radiol. 2013;24:1227-1234. [PMID: 23602420 DOI: 10.1016/j.jvir.2013.02.031] [Cited by in Crossref: 114] [Cited by in F6Publishing: 89] [Article Influence: 14.3] [Reference Citation Analysis]
115 Iavarone M, Colombo M. HBV-related HCC, clinical issues and therapy. Dig Liver Dis. 2011;43 Suppl 1:S32-S39. [PMID: 21195370 DOI: 10.1016/S1590-8658(10)60690-1] [Cited by in Crossref: 13] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
116 Chan AK, Hegarty C, Klass D, Yoshida E, Chung S, Liu DM, Ho SG, Harris AC. The Role of Contrast-Enhanced Ultrasound in Guiding Radiofrequency Ablation of Hepatocellular Carcinoma. Can Assoc Radiol J 2015;66:171-8. [DOI: 10.1016/j.carj.2014.11.005] [Cited by in Crossref: 18] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
117 Korean Liver Cancer Association., National Cancer Center. 2018 Korean Liver Cancer Association-National Cancer Center Korea Practice Guidelines for the Management of Hepatocellular Carcinoma. Gut Liver 2019;13:227-99. [PMID: 31060120 DOI: 10.5009/gnl19024] [Cited by in Crossref: 90] [Cited by in F6Publishing: 71] [Article Influence: 90.0] [Reference Citation Analysis]
118 Kennedy AS, Ball DS, Cohen SJ, Cohn M, Coldwell DM, Drooz A, Ehrenwald E, Kanani S, Nutting CW, Moeslein FM, Putnam SG 3rd, Rose SC, Savin MA, Schirm S, Sharma NK, Wang EA. Hepatic imaging response to radioembolization with yttrium-90-labeled resin microspheres for tumor progression during systemic chemotherapy in patients with colorectal liver metastases. J Gastrointest Oncol 2015;6:594-604. [PMID: 26697190 DOI: 10.3978/j.issn.2078-6891.2015.082] [Cited by in F6Publishing: 8] [Reference Citation Analysis]
119 Vivarelli M, Montalti R, Risaliti A. Multimodal treatment of hepatocellular carcinoma on cirrhosis: an update. World J Gastroenterol. 2013;19:7316-7326. [PMID: 24259963 DOI: 10.3748/wjg.v19.i42.7316] [Cited by in CrossRef: 25] [Cited by in F6Publishing: 22] [Article Influence: 3.6] [Reference Citation Analysis]
120 Yu SC, Hui EP, Tang P, Chan SK, Chu CC, Hui JW, Chan SL, Lee KF, Lai PB, Yeo W. Transarterial Ethanol Ablation for Unresectable Hepatocellular Carcinoma: Analysis of Clinical and Tumor Outcomes. J Vasc Interv Radiol 2016;27:639-49. [PMID: 26803574 DOI: 10.1016/j.jvir.2015.11.032] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
121 Rosenkrantz AB, Mendiratta-Lala M, Bartholmai BJ, Ganeshan D, Abramson RG, Burton KR, Yu JP, Scalzetti EM, Yankeelov TE, Subramaniam RM, Lenchik L. Clinical utility of quantitative imaging. Acad Radiol 2015;22:33-49. [PMID: 25442800 DOI: 10.1016/j.acra.2014.08.011] [Cited by in Crossref: 42] [Cited by in F6Publishing: 25] [Article Influence: 6.0] [Reference Citation Analysis]
122 Zhang Y, Lu Y, Zhang C, Huang D, Wu W, Zhang Y, Shen J, Cai Y, Chen W, Yao W. FSCN‑1 increases doxorubicin resistance in hepatocellular carcinoma through promotion of epithelial-mesenchymal transition. Int J Oncol 2018;52:1455-64. [PMID: 29568938 DOI: 10.3892/ijo.2018.4327] [Cited by in Crossref: 5] [Cited by in F6Publishing: 14] [Article Influence: 1.7] [Reference Citation Analysis]
123 Zhu AX, Duda DG, Sahani DV, Jain RK. HCC and angiogenesis: possible targets and future directions. Nat Rev Clin Oncol 2011;8:292-301. [PMID: 21386818 DOI: 10.1038/nrclinonc.2011.30] [Cited by in Crossref: 293] [Cited by in F6Publishing: 272] [Article Influence: 29.3] [Reference Citation Analysis]
124 Kielar AZ, Hibbert RM, Maturen KE. Imaging after local tumor therapies: kidney and liver. Semin Roentgenol 2013;48:273-84. [PMID: 23796378 DOI: 10.1053/j.ro.2013.03.002] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
125 Crocetti L, Della Pina C, Cioni D, Lencioni R. Peri-intraprocedural imaging: US, CT, and MRI. Abdom Imaging 2011;36:648-60. [DOI: 10.1007/s00261-011-9750-9] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 1.7] [Reference Citation Analysis]
126 Edeline J, Boucher E, Rolland Y, Vauléon E, Pracht M, Perrin C, Le Roux C, Raoul J. Comparison of tumor response by Response Evaluation Criteria in Solid Tumors (RECIST) and modified RECIST in patients treated with sorafenib for hepatocellular carcinoma: mRECIST Impact in Sorafenib-Treated HCC. Cancer 2012;118:147-56. [DOI: 10.1002/cncr.26255] [Cited by in Crossref: 191] [Cited by in F6Publishing: 163] [Article Influence: 19.1] [Reference Citation Analysis]
127 Martens MH, Lambregts DMJ, Kluza E, Beets-tan RGH. Tumor Response to Treatment: Prediction and Assessment. Curr Radiol Rep 2014;2. [DOI: 10.1007/s40134-014-0062-z] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 0.9] [Reference Citation Analysis]
128 Nouhaud E, Créhange G, Cueff A, Quivrin M, Rouffiac-Thouant M, Mineur L, Garcia R, Chamois J, Maingon P. Stereotactic Body radiation therapy for liver tumors with or without rotational intensity modulated radiation therapy. BMC Res Notes 2013;6:492. [PMID: 24279802 DOI: 10.1186/1756-0500-6-492] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
129 Dioguardi Burgio M, Ronot M, Bruno O, Francoz C, Paradis V, Castera L, Durand F, Soubrane O, Vilgrain V. Correlation of tumor response on computed tomography with pathological necrosis in hepatocellular carcinoma treated by chemoembolization before liver transplantation. Liver Transpl 2016;22:1491-500. [DOI: 10.1002/lt.24615] [Cited by in Crossref: 19] [Cited by in F6Publishing: 13] [Article Influence: 3.8] [Reference Citation Analysis]
130 Ko CC, Yeh LR, Kuo YT, Chen JH. Imaging biomarkers for evaluating tumor response: RECIST and beyond. Biomark Res 2021;9:52. [PMID: 34215324 DOI: 10.1186/s40364-021-00306-8] [Reference Citation Analysis]
131 Riaz A, Memon K, Miller FH, Nikolaidis P, Kulik LM, Lewandowski RJ, Ryu RK, Sato KT, Gates VL, Mulcahy MF. Role of the EASL, RECIST, and WHO response guidelines alone or in combination for hepatocellular carcinoma: radiologic-pathologic correlation. J Hepatol. 2011;54:695-704. [PMID: 21147504 DOI: 10.1016/j.jhep.2010.10.004] [Cited by in Crossref: 124] [Cited by in F6Publishing: 100] [Article Influence: 11.3] [Reference Citation Analysis]
132 Sawhney S, Montano-Loza AJ, Salat P, McCarthy M, Kneteman N, Meza-Junco J, Owen R. Transarterial chemoembolization in patients with hepatocellular carcinoma: predictors of survival. Can J Gastroenterol 2011;25:426-32. [PMID: 21912767 DOI: 10.1155/2011/864234] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
133 Minami Y, Kudo M. Therapeutic response assessment of transcatheter arterial chemoembolization for hepatocellular carcinoma: ultrasonography, CT and MR imaging. Oncology. 2013;84 Suppl 1:58-63. [PMID: 23428860 DOI: 10.1159/000345891] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
134 Garin E, Lenoir L, Rolland Y, Edeline J, Mesbah H, Laffont S, Porée P, Clément B, Raoul JL, Boucher E. Dosimetry based on 99mTc-macroaggregated albumin SPECT/CT accurately predicts tumor response and survival in hepatocellular carcinoma patients treated with 90Y-loaded glass microspheres: preliminary results. J Nucl Med. 2012;53:255-263. [PMID: 22302962 DOI: 10.2967/jnumed.111.094235] [Cited by in Crossref: 170] [Cited by in F6Publishing: 124] [Article Influence: 18.9] [Reference Citation Analysis]
135 Felker ER, Dregely I, Chung DJ, Sung K, Osuagwu FC, Lassman C, Sayre J, Wu H, Lu DS. Irreversible Electroporation: Defining the MRI Appearance of the Ablation Zone With Histopathologic Correlation in a Porcine Liver Model. AJR Am J Roentgenol. 2017;208:1141-1146. [PMID: 28177652 DOI: 10.2214/ajr.16.17207] [Cited by in Crossref: 10] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
136 Bonekamp S, Shen J, Salibi N, Lai HC, Geschwind J, Kamel IR. Early response of hepatic malignancies to locoregional therapy-value of diffusion-weighted magnetic resonance imaging and proton magnetic resonance spectroscopy. J Comput Assist Tomogr. 2011;35:167-173. [PMID: 21412085 DOI: 10.1097/rct.0b013e3182004bfb] [Cited by in Crossref: 17] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
137 Bouda D, Lagadec M, Alba CG, Barrau V, Dioguardi Burgio M, Moussa N, Vilgrain V, Ronot M. Imaging review of hepatocellular carcinoma after thermal ablation: The good, the bad, and the ugly: Imaging of HCC After Thermal Ablation. J Magn Reson Imaging 2016;44:1070-90. [DOI: 10.1002/jmri.25369] [Cited by in Crossref: 13] [Cited by in F6Publishing: 7] [Article Influence: 2.6] [Reference Citation Analysis]
138 Cucchetti A, Cescon M, Bigonzi E, Piscaglia F, Golfieri R, Ercolani G, Cristina Morelli M, Ravaioli M, Daniele Pinna A. Priority of candidates with hepatocellular carcinoma awaiting liver transplantation can be reduced after successful bridge therapy. Liver Transpl. 2011;17:1344-1354. [PMID: 21837731 DOI: 10.1002/lt.22397] [Cited by in Crossref: 67] [Cited by in F6Publishing: 58] [Article Influence: 7.4] [Reference Citation Analysis]
139 Ohri N, Dawson LA, Krishnan S, Seong J, Cheng JC, Sarin SK, Kinkhabwala M, Ahmed MM, Vikram B, Coleman CN, Guha C. Radiotherapy for Hepatocellular Carcinoma: New Indications and Directions for Future Study. J Natl Cancer Inst. 2016;108. [PMID: 27377923 DOI: 10.1093/jnci/djw133] [Cited by in Crossref: 36] [Cited by in F6Publishing: 28] [Article Influence: 7.2] [Reference Citation Analysis]
140 Bruix J, Chan SL, Galle PR, Rimassa L, Sangro B. Systemic treatment of hepatocellular carcinoma: An EASL position paper. J Hepatol 2021:S0168-8278(21)01903-6. [PMID: 34256065 DOI: 10.1016/j.jhep.2021.07.004] [Cited by in Crossref: 4] [Article Influence: 4.0] [Reference Citation Analysis]
141 Schraml C, Schwenzer NF, Martirosian P, Bitzer M, Lauer U, Claussen CD, Horger M. Diffusion-weighted MRI of advanced hepatocellular carcinoma during sorafenib treatment: initial results. AJR Am J Roentgenol. 2009;193:W301-W307. [PMID: 19770299 DOI: 10.2214/ajr.08.2289] [Cited by in Crossref: 73] [Cited by in F6Publishing: 37] [Article Influence: 6.1] [Reference Citation Analysis]
142 Kim BK, Kim KA, Park JY, Ahn SH, Chon CY, Han KH, Kim SU, Kim MJ. Prospective comparison of prognostic values of modified Response Evaluation Criteria in Solid Tumours with European Association for the Study of the Liver criteria in hepatocellular carcinoma following chemoembolisation. Eur J Cancer. 2013;49:826-834. [PMID: 22995582 DOI: 10.1016/j.ejca.2012.08.022] [Cited by in Crossref: 59] [Cited by in F6Publishing: 53] [Article Influence: 6.6] [Reference Citation Analysis]
143 He AR, Goldenberg AS. Treating hepatocellular carcinoma progression following first-line sorafenib: therapeutic options and clinical observations. Therap Adv Gastroenterol 2013;6:447-58. [PMID: 24179481 DOI: 10.1177/1756283X13498540] [Cited by in Crossref: 19] [Cited by in F6Publishing: 9] [Article Influence: 2.4] [Reference Citation Analysis]
144 Park C, Gwon DI, Chu HH, Kim JW, Kim JH, Ko GY. Correlation of tumor response on CT with pathologically proven necrosis in hepatocellular carcinoma treated by conventional transcatheter arterial chemoembolization: threshold value of intratumoral Lipiodol accumulation predicting tumor necrosis. Abdom Radiol (NY) 2021;46:3729-37. [PMID: 33141259 DOI: 10.1007/s00261-020-02845-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
145 Ayuso C, Rimola J, García-Criado A. Imaging of HCC. Abdom Imaging. 2012;37:215-230. [PMID: 21909721 DOI: 10.1007/s00261-011-9794-x] [Cited by in Crossref: 51] [Cited by in F6Publishing: 34] [Article Influence: 5.7] [Reference Citation Analysis]
146 Ronot M, Lambert S, Daire J, Lagadec M, Doblas S, Garteiser P, Kerbaol A, Sinkus R, Van Beers B, Vilgrain V. Can we justify not doing liver perfusion imaging in 2013? Diagnostic and Interventional Imaging 2013;94:1323-36. [DOI: 10.1016/j.diii.2013.06.005] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
147 Yu SCH, Hui JWY, Chong CCN, Chu CM, Cheung S, Wong J, Lee KF. Transarterial Ethanol Ablation for Small Hepatocellular Carcinoma (≤ 3 cm): A Comparative Study Versus Radiofrequency Ablation. Cardiovasc Intervent Radiol 2020;43:732-9. [PMID: 32152720 DOI: 10.1007/s00270-020-02426-4] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
148 Raoul JL, Park JW, Kang YK, Finn RS, Kim JS, Yeo W, Polite BN, Chao Y, Walters I, Baudelet C, Lencioni R. Using Modified RECIST and Alpha-Fetoprotein Levels to Assess Treatment Benefit in Hepatocellular Carcinoma. Liver Cancer 2014;3:439-50. [PMID: 26280005 DOI: 10.1159/000343872] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 2.2] [Reference Citation Analysis]
149 Riaz A, Gabr A, Abouchaleh N, Ali R, Al Asadi A, Mora R, Kulik L, Desai K, Thornburg B, Mouli S, Hickey R, Miller FH, Yaghmai V, Ganger D, Lewandowski RJ, Salem R. Radioembolization for hepatocellular carcinoma: Statistical confirmation of improved survival in responders by landmark analyses: Riaz et al. Hepatology 2018;67:873-83. [DOI: 10.1002/hep.29480] [Cited by in Crossref: 29] [Cited by in F6Publishing: 18] [Article Influence: 9.7] [Reference Citation Analysis]
150 Müller L, Stoehr F, Mähringer-Kunz A, Hahn F, Weinmann A, Kloeckner R. Current Strategies to Identify Patients That Will Benefit from TACE Treatment and Future Directions a Practical Step-by-Step Guide. J Hepatocell Carcinoma 2021;8:403-19. [PMID: 34012930 DOI: 10.2147/JHC.S285735] [Reference Citation Analysis]
151 Wulfert S, Kratochwil C, Choyke PL, Afshar-Oromieh A, Mier W, Kauczor HU, Schenk JP, Haberkorn U, Giesel FL. Multimodal imaging for early functional response assessment of (90)Y-/ (177)Lu-DOTATOC peptide receptor targeted radiotherapy with DW-MRI and (68)Ga-DOTATOC-PET/CT. Mol Imaging Biol 2014;16:586-94. [PMID: 24526358 DOI: 10.1007/s11307-014-0722-7] [Cited by in Crossref: 22] [Cited by in F6Publishing: 16] [Article Influence: 3.7] [Reference Citation Analysis]
152 Gonzalez-guindalini FD, Botelho MPF, Harmath CB, Sandrasegaran K, Miller FH, Salem R, Yaghmai V. Assessment of Liver Tumor Response to Therapy: Role of Quantitative Imaging. RadioGraphics 2013;33:1781-800. [DOI: 10.1148/rg.336135511] [Cited by in Crossref: 48] [Cited by in F6Publishing: 40] [Article Influence: 6.0] [Reference Citation Analysis]
153 Du F, Jiang R, Gu M, He C, Guan J. The clinical application of 320-detector row CT in transcatheter arterial chemoembolization (TACE) for hepatocellular carcinoma. Radiol med 2015;120:690-4. [DOI: 10.1007/s11547-015-0523-3] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
154 Tochetto SM, Töre HG, Chalian H, Yaghmai V. Colorectal Liver Metastasis After 90 Y Radioembolization Therapy: Pilot Study of Change in MDCT Attenuation as a Surrogate Marker for Future FDG PET Response. American Journal of Roentgenology 2012;198:1093-9. [DOI: 10.2214/ajr.11.6622] [Cited by in Crossref: 10] [Cited by in F6Publishing: 4] [Article Influence: 1.1] [Reference Citation Analysis]
155 Vande Lune P, Abdel Aal AK, Klimkowski S, Zarzour JG, Gunn AJ. Hepatocellular Carcinoma: Diagnosis, Treatment Algorithms, and Imaging Appearance after Transarterial Chemoembolization. J Clin Transl Hepatol 2018;6:175-88. [PMID: 29951363 DOI: 10.14218/JCTH.2017.00045] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
156 Cárdenes HR, Lasley F. Primary Liver Cancer. In: Lo SS, Teh BS, Lu JJ, Schefter TE, editors. Stereotactic Body Radiation Therapy. Berlin: Springer Berlin Heidelberg; 2012. pp. 163-82. [DOI: 10.1007/174_2012_548] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
157 Delumeau S, Lebigot J, Ridereau-zins C, Bouvier A, Boursier J, Aubé C. Aspects et évaluation post-thérapeutiques des lésions du foie après traitement non chirurgical. Journal de Radiologie 2011;92:632-58. [DOI: 10.1016/j.jradio.2011.04.014] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
158 Kim MJ, Choi JI, Lee JS, Park JW. Computed tomography findings of sorafenib-treated hepatic tumors in patients with advanced hepatocellular carcinoma. J Gastroenterol Hepatol. 2011;26:1201-1206. [PMID: 21371120 DOI: 10.1111/j.1440-1746.2011.06709.x] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
159 Odisio BC, Galastri F, Avritscher R, Afonso BB, Segatelli V, Felga GE, Salvalaggio PR, Ensor J, Wallace MJ, Nasser F. Hepatocellular carcinomas within the Milan criteria: predictors of histologic necrosis after drug-eluting beads transarterial chemoembolization. Cardiovasc Intervent Radiol. 2014;37:1018-1026. [PMID: 24149832 DOI: 10.1007/s00270-013-0759-z] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
160 Grand DJ, Beland M, Noto RB, Mayo-Smith W. Optimum imaging of colorectal metastases. J Surg Oncol 2010;102:909-13. [PMID: 21165992 DOI: 10.1002/jso.21656] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
161 Hyder O, Dodson RM, Weiss M, Cosgrove DP, Herman JM, Geschwind JH, Kamel IR, Pawlik TM. Trends and patterns of utilization in post-treatment surveillance imaging among patients treated for hepatocellular carcinoma. J Gastrointest Surg. 2013;17:1774-1783. [PMID: 23943387 DOI: 10.1007/s11605-013-2302-6] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 1.8] [Reference Citation Analysis]
162 Garin E, Tselikas L, Guiu B, Chalaye J, Edeline J, de Baere T, Assenat E, Tacher V, Robert C, Terroir-Cassou-Mounat M, Mariano-Goulart D, Amaddeo G, Palard X, Hollebecque A, Kafrouni M, Regnault H, Boudjema K, Grimaldi S, Fourcade M, Kobeiter H, Vibert E, Le Sourd S, Piron L, Sommacale D, Laffont S, Campillo-Gimenez B, Rolland Y; DOSISPHERE-01 Study Group. Personalised versus standard dosimetry approach of selective internal radiation therapy in patients with locally advanced hepatocellular carcinoma (DOSISPHERE-01): a randomised, multicentre, open-label phase 2 trial. Lancet Gastroenterol Hepatol 2021;6:17-29. [PMID: 33166497 DOI: 10.1016/S2468-1253(20)30290-9] [Cited by in Crossref: 25] [Cited by in F6Publishing: 10] [Article Influence: 25.0] [Reference Citation Analysis]
163 Cheng AL, Amarapurkar D, Chao Y, Chen P, Geschwind J, Goh KL, Han K, Kudo M, Lee HC, Lee R, Lesmana LA, Lim HY, Paik SW, Poon RT, Tan C, Tanwandee T, Teng G, Park J. Re-evaluating transarterial chemoembolization for the treatment of Hepatocellular Carcinoma: Consensus recommendations and review by an International Expert Panel. Liver Int 2014;34:174-83. [DOI: 10.1111/liv.12314] [Cited by in Crossref: 38] [Cited by in F6Publishing: 37] [Article Influence: 4.8] [Reference Citation Analysis]
164 Kouloulias V, Mosa E, Georgakopoulos J, Platoni K, Brountzos I, Zygogianni A, Antypas C, Kosmidis P, Mystakidou K, Tolia M. Three-dimensional conformal radiotherapy for hepatocellular carcinoma in patients unfit for resection, ablation, or chemotherapy: a retrospective study. ScientificWorldJournal. 2013;2013:780141. [PMID: 24379750 DOI: 10.1155/2013/780141] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
165 Bruix J, Reig M, Rimola J, Forner A, Burrel M, Vilana R, Ayuso C. Clinical decision making and research in hepatocellular carcinoma: pivotal role of imaging techniques. Hepatology. 2011;54:2238-2244. [PMID: 21932394 DOI: 10.1002/hep.24670] [Cited by in Crossref: 78] [Cited by in F6Publishing: 60] [Article Influence: 8.7] [Reference Citation Analysis]
166 Wehling C, Hornuss D, Schneider P, Springfeld C, Hoffmann K, Chang D, Naumann P, Mieth M, Longerich T, Kratochwil C, Mehrabi A, Gauss A, Weiss KH, Pfeiffenberger J. Impact of interventions and tumor stage on health-related quality of life in patients with hepatocellular carcinoma. J Cancer Res Clin Oncol 2019;145:2761-9. [DOI: 10.1007/s00432-019-03005-y] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
167 Tanguturi SK, Wo JY, Zhu AX, Dawson LA, Hong TS. Radiation therapy for liver tumors: ready for inclusion in guidelines? Oncologist. 2014;19:868-879. [PMID: 25001265 DOI: 10.1634/theoncologist.2014-0097] [Cited by in Crossref: 42] [Cited by in F6Publishing: 25] [Article Influence: 6.0] [Reference Citation Analysis]
168 Zhao Y, Duran R, Bai W, Sahu S, Wang W, Kabus S, Lin M, Han G, Geschwind JF. Which Criteria Applied in Multi-Phasic CT Can Predict Early Tumor Response in Patients with Hepatocellular Carcinoma Treated Using Conventional TACE: RECIST, mRECIST, EASL or qEASL? Cardiovasc Intervent Radiol. 2018;41:433-442. [PMID: 29086058 DOI: 10.1007/s00270-017-1829-4] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
169 Ronot M, Clift AK, Vilgrain V, Frilling A. Functional imaging in liver tumours. J Hepatol 2016;65:1017-30. [PMID: 27395013 DOI: 10.1016/j.jhep.2016.06.024] [Cited by in Crossref: 31] [Cited by in F6Publishing: 25] [Article Influence: 6.2] [Reference Citation Analysis]
170 Baimas-George M, Watson M, Sulzer J, Salibi P, Murphy KJ, Levi D, Martinie JB, Vrochides D, Baker EH, Ocuin L, Iannitti DA. Pathologic response translates to improved patient survival after locoregional treatment for hepatocellular carcinoma: the importance of minimally invasive microwave ablation. Surg Endosc 2021;35:3122-30. [PMID: 32588344 DOI: 10.1007/s00464-020-07747-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
171 Lee CH, Braga L, de Campos RO, Semelka RC. Hepatic tumor response evaluation by MRI: HEPATIC TUMOR RESPONSE EVALUATION BY MRI. NMR Biomed 2011;24:721-33. [DOI: 10.1002/nbm.1637] [Cited by in Crossref: 19] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
172 Aliberti C, Carandina R, Sarti D, Mulazzani L, Pizzirani E, Guadagni S, Fiorentini G. Chemoembolization Adopting Polyethylene Glycol Drug-Eluting Embolics Loaded With Doxorubicin for the Treatment of Hepatocellular Carcinoma. American Journal of Roentgenology 2017;209:430-4. [DOI: 10.2214/ajr.16.17477] [Cited by in Crossref: 15] [Cited by in F6Publishing: 5] [Article Influence: 3.8] [Reference Citation Analysis]
173 Granata V, Petrillo M, Fusco R, Setola SV, de Lutio di Castelguidone E, Catalano O, Piccirillo M, Albino V, Izzo F, Petrillo A. Surveillance of HCC Patients after Liver RFA: Role of MRI with Hepatospecific Contrast versus Three-Phase CT Scan-Experience of High Volume Oncologic Institute. Gastroenterol Res Pract 2013;2013:469097. [PMID: 24324487 DOI: 10.1155/2013/469097] [Cited by in Crossref: 35] [Cited by in F6Publishing: 23] [Article Influence: 4.4] [Reference Citation Analysis]
174 Willatt J, Ruma JA, Azar SF, Dasika NL, Syed F. Imaging of hepatocellular carcinoma and image guided therapies - how we do it. Cancer Imaging 2017;17:9. [PMID: 28259177 DOI: 10.1186/s40644-017-0110-z] [Cited by in Crossref: 10] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
175 Padia SA, Lewandowski RJ, Johnson GE, Sze DY, Ward TJ, Gaba RC, Baerlocher MO, Gates VL, Riaz A, Brown DB, Siddiqi NH, Walker TG, Silberzweig JE, Mitchell JW, Nikolic B, Salem R. Radioembolization of Hepatic Malignancies: Background, Quality Improvement Guidelines, and Future Directions. Journal of Vascular and Interventional Radiology 2017;28:1-15. [DOI: 10.1016/j.jvir.2016.09.024] [Cited by in Crossref: 54] [Cited by in F6Publishing: 29] [Article Influence: 13.5] [Reference Citation Analysis]
176 Lencioni R. Chemoembolization in patients with hepatocellular carcinoma. Liver Cancer. 2012;1:41-50. [PMID: 24159570 DOI: 10.1159/000339019] [Cited by in Crossref: 28] [Cited by in F6Publishing: 41] [Article Influence: 4.0] [Reference Citation Analysis]
177 Akisik MF, Sandrasegaran K, Bu G, Lin C, Hutchins GD, Chiorean EG. Pancreatic cancer: utility of dynamic contrast-enhanced MR imaging in assessment of antiangiogenic therapy. Radiology. 2010;256:441-449. [PMID: 20515976 DOI: 10.1148/radiol.10091733] [Cited by in Crossref: 77] [Cited by in F6Publishing: 55] [Article Influence: 7.0] [Reference Citation Analysis]
178 Li Z, Si G, Jiao DC, Han X, Zhang W, Li Y, Zhou X, Liu J, Chen J. Portal Vein Stenting Combined with 125I Particle Chain Implantation Followed by As2O3 in the Treatment of Hepatocellular Carcinoma with Portal Vein Tumour Thrombus. Biomed Res Int 2020;2020:4109216. [PMID: 32090088 DOI: 10.1155/2020/4109216] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
179 Pesapane F, Nezami N, Patella F, Geschwind JF. New concepts in embolotherapy of HCC. Med Oncol. 2017;34:58. [PMID: 28299645 DOI: 10.1007/s12032-017-0917-2] [Cited by in Crossref: 32] [Cited by in F6Publishing: 22] [Article Influence: 8.0] [Reference Citation Analysis]
180 Golfieri R, Renzulli M, Mosconi C, Forlani L, Giampalma E, Piscaglia F, Trevisani F, Bolondi L. Hepatocellular carcinoma responding to superselective transarterial chemoembolization: an issue of nodule dimension? J Vasc Interv Radiol. 2013;24:509-517. [PMID: 23428355 DOI: 10.1016/j.jvir.2012.12.013] [Cited by in Crossref: 55] [Cited by in F6Publishing: 45] [Article Influence: 6.9] [Reference Citation Analysis]
181 Yamamoto K, Yamanaka K, Hatano E, Sumi E, Ishii T, Taura K, Iguchi K, Teramukai S, Yokode M, Uemoto S, Fukushima M. An eClinical trial system for cancer that integrates with clinical pathways and electronic medical records. Clin Trials 2012;9:408-17. [PMID: 22605791 DOI: 10.1177/1740774512445912] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
182 Rammohan A, Sathyanesan J, Ramaswami S, Lakshmanan A, Senthil-Kumar P, Srinivasan UP, Ramasamy R, Ravichandran P. Embolization of liver tumors: Past, present and future. World J Radiol. 2012;4:405-412. [PMID: 23024842 DOI: 10.4329/wjr.v4.i9.405] [Cited by in CrossRef: 44] [Cited by in F6Publishing: 33] [Article Influence: 4.9] [Reference Citation Analysis]
183 Goh V, Sarker D, Osmany S, Cook GJ. Functional imaging techniques in hepatocellular carcinoma. Eur J Nucl Med Mol Imaging. 2012;39:1070-1079. [PMID: 22434049 DOI: 10.1007/s00259-012-2096-x] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
184 Kim KW, Lee JM, Choi BI. Assessment of the treatment response of HCC. Abdom Imaging. 2011;36:300-314. [PMID: 21279353 DOI: 10.1007/s00261-011-9683-3] [Cited by in Crossref: 42] [Cited by in F6Publishing: 29] [Article Influence: 4.2] [Reference Citation Analysis]
185 Lv W, Yan T, Wang G, Zhao W, Zhang T, Zhou D. High-intensity focused ultrasound therapy in combination with gemcitabine for unresectable pancreatic carcinoma. Ther Clin Risk Manag 2016;12:687-91. [PMID: 27194912 DOI: 10.2147/TCRM.S90567] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
186 Salem R, Lewandowski RJ, Kulik L, Wang E, Riaz A, Ryu RK, Sato KT, Gupta R, Nikolaidis P, Miller FH, Yaghmai V, Ibrahim SM, Senthilnathan S, Baker T, Gates VL, Atassi B, Newman S, Memon K, Chen R, Vogelzang RL, Nemcek AA, Resnick SA, Chrisman HB, Carr J, Omary RA, Abecassis M, Benson AB, Mulcahy MF. Radioembolization results in longer time-to-progression and reduced toxicity compared with chemoembolization in patients with hepatocellular carcinoma. Gastroenterology. 2011;140:497-507.e2. [PMID: 21044630 DOI: 10.1053/j.gastro.2010.10.049] [Cited by in Crossref: 390] [Cited by in F6Publishing: 323] [Article Influence: 35.5] [Reference Citation Analysis]
187 Sahin H, Harman M, Cinar C, Bozkaya H, Parildar M, Elmas N. Evaluation of treatment response of chemoembolization in hepatocellular carcinoma with diffusion-weighted imaging on 3.0-T MR imaging. J Vasc Interv Radiol. 2012;23:241-247. [PMID: 22019180 DOI: 10.1016/j.jvir.2011.08.030] [Cited by in Crossref: 34] [Cited by in F6Publishing: 26] [Article Influence: 3.4] [Reference Citation Analysis]
188 Nicolini D, Svegliati-Baroni G, Candelari R, Mincarelli C, Mandolesi A, Bearzi I, Mocchegiani F, Vecchi A, Montalti R, Benedetti A, Risaliti A, Vivarelli M. Doxorubicin-eluting bead vs conventional transcatheter arterial chemoembolization for hepatocellular carcinoma before liver transplantation. World J Gastroenterol 2013;19:5622-32. [PMID: 24039354 DOI: 10.3748/wjg.v19.i34.5622] [Cited by in CrossRef: 40] [Cited by in F6Publishing: 31] [Article Influence: 5.7] [Reference Citation Analysis]
189 Duran R, Chapiro J, Schernthaner RE, Geschwind JF. Systematic review of catheter-based intra-arterial therapies in hepatocellular carcinoma: state of the art and future directions. Br J Radiol. 2015;88:20140564. [PMID: 25978585 DOI: 10.1259/bjr.20140564] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 2.7] [Reference Citation Analysis]
190 Riaz A, Lewandowski RJ, Kulik L, Ryu RK, Mulcahy MF, Baker T, Gates V, Nayar R, Wang E, Miller FH. Radiologic-pathologic correlation of hepatocellular carcinoma treated with chemoembolization. Cardiovasc Intervent Radiol. 2010;33:1143-1152. [PMID: 19967371 DOI: 10.1007/s00270-009-9766-5] [Cited by in Crossref: 77] [Cited by in F6Publishing: 63] [Article Influence: 6.4] [Reference Citation Analysis]
191 Memon K, Lewandowski RJ, Kulik L, Riaz A, Mulcahy MF, Salem R. Radioembolization for primary and metastatic liver cancer. Semin Radiat Oncol. 2011;21:294-302. [PMID: 21939859 DOI: 10.1016/j.semradonc.2011.05.004] [Cited by in Crossref: 51] [Cited by in F6Publishing: 30] [Article Influence: 5.7] [Reference Citation Analysis]
192 Zheng SG, Xu HX, Liu LN. Management of hepatocellular carcinoma: The role of contrast-enhanced ultrasound. World J Radiol 2014;6:7-14. [PMID: 24578787 DOI: 10.4329/wjr.v6.i1.7] [Cited by in CrossRef: 38] [Cited by in F6Publishing: 36] [Article Influence: 5.4] [Reference Citation Analysis]
193 Garin E, Lenoir L, Edeline J, Laffont S, Mesbah H, Porée P, Sulpice L, Boudjema K, Mesbah M, Guillygomarc’h A. Boosted selective internal radiation therapy with 90Y-loaded glass microspheres (B-SIRT) for hepatocellular carcinoma patients: a new personalized promising concept. Eur J Nucl Med Mol Imaging. 2013;40:1057-1068. [PMID: 23613103 DOI: 10.1007/s00259-013-2395-x] [Cited by in Crossref: 116] [Cited by in F6Publishing: 82] [Article Influence: 14.5] [Reference Citation Analysis]
194 Bargellini I, Bozzi E, Campani D, Carrai P, De Simone P, Pollina L, Cioni R, Filipponi F, Bartolozzi C. Modified RECIST to assess tumor response after transarterial chemoembolization of hepatocellular carcinoma: CT-pathologic correlation in 178 liver explants. Eur J Radiol. 2013;82:e212-e218. [PMID: 23332890 DOI: 10.1016/j.ejrad.2012.12.009] [Cited by in Crossref: 57] [Cited by in F6Publishing: 51] [Article Influence: 7.1] [Reference Citation Analysis]
195 Prajapati HJ, Spivey JR, Hanish SI, El-Rayes BF, Kauh JS, Chen Z, Kim HS. mRECIST and EASL responses at early time point by contrast-enhanced dynamic MRI predict survival in patients with unresectable hepatocellular carcinoma (HCC) treated by doxorubicin drug-eluting beads transarterial chemoembolization (DEB TACE). Ann Oncol. 2013;24:965-973. [PMID: 23223331 DOI: 10.1093/annonc/mds605] [Cited by in Crossref: 75] [Cited by in F6Publishing: 70] [Article Influence: 8.3] [Reference Citation Analysis]
196 Janoray G, Mornex F. Suivi après radiothérapie stéréotaxique des tumeurs hépatiques : revue de la littérature et recommandations. Cancer/Radiothérapie 2015;19:573-81. [DOI: 10.1016/j.canrad.2015.05.020] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
197 Forner A, Gilabert M, Bruix J, Raoul JL. Treatment of intermediate-stage hepatocellular carcinoma. Nat Rev Clin Oncol. 2014;11:525-535. [PMID: 25091611 DOI: 10.1038/nrclinonc.2014] [Reference Citation Analysis]
198 Peungjesada S, Chuang HH, Prasad SR, Choi H, Loyer EM, Bronstein Y. Evaluation of cancer treatment in the abdomen: Trends and advances. World J Radiol 2013;5:126-42. [PMID: 23671749 DOI: 10.4329/wjr.v5.i3.126] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
199 Kloeckner R, Galle PR, Bruix J. Local and Regional Therapies for Hepatocellular Carcinoma. Hepatology 2021;73 Suppl 1:137-49. [PMID: 32557715 DOI: 10.1002/hep.31424] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 10.0] [Reference Citation Analysis]
200 Zhang Q, Chen Y, Bai X, Liang T. Immune Checkpoint Blockade Therapy for Hepatocellular Carcinoma: Clinical Challenges and Considerations. Front Oncol 2020;10:590058. [PMID: 33178615 DOI: 10.3389/fonc.2020.590058] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
201 Bartnik K, Podgórska J, Rosiak G, Korzeniowski K, Giziński J, Sajdek M, Wróblewski T, Zieniewicz K, Nyckowski P, Rowiński O. Performance of initial LI-RADS 2018 treatment response in predicting survival of patients with hepatocellular carcinoma following TACE: a retrospective, single-center cohort study. J Cancer Res Clin Oncol 2021. [PMID: 33778924 DOI: 10.1007/s00432-021-03603-9] [Reference Citation Analysis]
202 Kafrouni M, Allimant C, Fourcade M, Vauclin S, Delicque J, Ilonca A, Guiu B, Manna F, Molinari N, Mariano-goulart D, Ben Bouallègue F. Retrospective Voxel-Based Dosimetry for Assessing the Ability of the Body-Surface-Area Model to Predict Delivered Dose and Radioembolization Outcome. J Nucl Med 2018;59:1289-95. [DOI: 10.2967/jnumed.117.202937] [Cited by in Crossref: 18] [Cited by in F6Publishing: 11] [Article Influence: 6.0] [Reference Citation Analysis]
203 Miura JT, Gamblin TC. Transarterial chemoembolization for primary liver malignancies and colorectal liver metastasis. Surg Oncol Clin N Am 2015;24:149-66. [PMID: 25444473 DOI: 10.1016/j.soc.2014.09.004] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
204 Kim HC, Suk KT, Kim DJ, Yoon JH, Kim YS, Baik GH, Kim JB, Kim CH, Sung H, Choi JY, Han KH, Park SH. Transarterial chemoembolization in Barcelona Clinic Liver Cancer Stage 0/A hepatocellular carcinoma. World J Gastroenterol 2014;20:745-54. [PMID: 24574748 DOI: 10.3748/wjg.v20.i3.745] [Cited by in CrossRef: 15] [Cited by in F6Publishing: 10] [Article Influence: 2.1] [Reference Citation Analysis]
205 Shanbhogue AK, Karnad AB, Prasad SR. Tumor response evaluation in oncology: current update. J Comput Assist Tomogr. 2010;34:479-484. [PMID: 20657213 DOI: 10.1097/RCT.0b013e3181db2670] [Cited by in Crossref: 33] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
206 Park SY, Kim JH, Yoon HJ, Lee IS, Yoon HK, Kim KP. Transarterial chemoembolization vs supportive therapy in the palliative treatment of unresectable intrahepatic cholangiocarcinoma. Clin Radiol. 2011;66:322-328. [PMID: 21356394 DOI: 10.1016/j.crad.2010.11.002] [Cited by in Crossref: 87] [Cited by in F6Publishing: 72] [Article Influence: 8.7] [Reference Citation Analysis]
207 Price TR, Perkins SM, Sandrasegaran K, Henderson MA, Maluccio MA, Zook JE, Tector AJ, Vianna RM, Johnstone PA, Cardenes HR. Evaluation of response after stereotactic body radiotherapy for hepatocellular carcinoma. Cancer. 2012;118:3191-3198. [PMID: 22025126 DOI: 10.1002/cncr.26404] [Cited by in Crossref: 86] [Cited by in F6Publishing: 73] [Article Influence: 8.6] [Reference Citation Analysis]
208 Akhlaghpoor S, Aziz-Ahari A, Amoui M, Tolooee S, Poorbeigi H, Sheybani S. Short-term effectiveness of radiochemoembolization for selected hepatic metastases with a combination protocol. World J Gastroenterol 2012;18:5249-59. [PMID: 23066320 DOI: 10.3748/wjg.v18.i37.5249] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
209 Hartenbach M, Weber S, Albert NL, Hartenbach S, Hirtl A, Zacherl MJ, Paprottka PM, Tiling R, Bartenstein P, Hacker M, Haug AR. Evaluating Treatment Response of Radioembolization in Intermediate-Stage Hepatocellular Carcinoma Patients Using 18F-Fluoroethylcholine PET/CT. J Nucl Med 2015;56:1661-6. [PMID: 26405170 DOI: 10.2967/jnumed.115.158758] [Cited by in Crossref: 19] [Cited by in F6Publishing: 6] [Article Influence: 3.2] [Reference Citation Analysis]
210 Liapi E, Geschwind JF. Transcatheter arterial chemoembolization for liver cancer: is it time to distinguish conventional from drug-eluting chemoembolization? Cardiovasc Intervent Radiol. 2011;34:37-49. [PMID: 21069333 DOI: 10.1007/s00270-010-0012-y] [Cited by in Crossref: 77] [Cited by in F6Publishing: 62] [Article Influence: 7.0] [Reference Citation Analysis]
211 Huertas A, Baumann AS, Saunier-Kubs F, Salleron J, Oldrini G, Croisé-Laurent V, Barraud H, Ayav A, Bronowicki JP, Peiffert D. Stereotactic body radiation therapy as an ablative treatment for inoperable hepatocellular carcinoma. Radiother Oncol. 2015;115:211-216. [PMID: 26028227 DOI: 10.1016/j.radonc.2015.04.006] [Cited by in Crossref: 82] [Cited by in F6Publishing: 53] [Article Influence: 13.7] [Reference Citation Analysis]
212 Hickey R, Vouche M, Sze DY, Hohlastos E, Collins J, Schirmang T, Memon K, Ryu RK, Sato K, Chen R, Gupta R, Resnick S, Carr J, Chrisman HB, Nemcek AA Jr, Vogelzang RL, Lewandowski RJ, Salem R. Cancer concepts and principles: primer for the interventional oncologist-part I. J Vasc Interv Radiol 2013;24:1157-64. [PMID: 23809510 DOI: 10.1016/j.jvir.2013.04.024] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
213 Maluccio M, Covey A. Recent progress in understanding, diagnosing, and treating hepatocellular carcinoma. CA: A Cancer Journal for Clinicians 2012;62:394-9. [DOI: 10.3322/caac.21161] [Cited by in Crossref: 498] [Cited by in F6Publishing: 475] [Article Influence: 55.3] [Reference Citation Analysis]
214 Aghighi M, Boe J, Rosenberg J, Von Eyben R, Gawande RS, Petit P, Sethi TK, Sharib J, Marina NM, DuBois SG, Daldrup-Link HE. Three-dimensional Radiologic Assessment of Chemotherapy Response in Ewing Sarcoma Can Be Used to Predict Clinical Outcome. Radiology 2016;280:905-15. [PMID: 26982677 DOI: 10.1148/radiol.2016151301] [Cited by in Crossref: 21] [Cited by in F6Publishing: 11] [Article Influence: 4.2] [Reference Citation Analysis]
215 Sato Y, Watanabe H, Sone M, Onaya H, Sakamoto N, Osuga K, Takahashi M, Arai Y. Tumor response evaluation criteria for HCC (hepatocellular carcinoma) treated using TACE (transcatheter arterial chemoembolization): RECIST (response evaluation criteria in solid tumors) version 1.1 and mRECIST (modified RECIST): JIVROSG-0602. Ups J Med Sci. 2013;118:16-22. [PMID: 23167460 DOI: 10.3109/03009734.2012.729104] [Cited by in Crossref: 37] [Cited by in F6Publishing: 30] [Article Influence: 4.1] [Reference Citation Analysis]
216 Memon K, Lewandowski RJ, Riaz A, Salem R. Yttrium 90 microspheres for the treatment of hepatocellular carcinoma. Recent Results Cancer Res. 2013;190:207-224. [PMID: 22941023 DOI: 10.1007/978-3-642-16037-0_14] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 2.5] [Reference Citation Analysis]
217 Wehling C, Dill MT, Olkus A, Springfeld C, Chang DH, Naumann P, Longerich T, Kratochwil C, Mehrabi A, Merle U, Pfeiffenberger J, Rupp C, Weiss KH, Mieth M. Treatment stage migration and treatment sequences in patients with hepatocellular carcinoma: drawbacks and opportunities. J Cancer Res Clin Oncol 2021;147:2471-81. [PMID: 33537908 DOI: 10.1007/s00432-021-03528-3] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
218 Subbiah V, Chuang HH, Gambhire D, Kairemo K. Defining Clinical Response Criteria and Early Response Criteria for Precision Oncology: Current State-of-the-Art and Future Perspectives. Diagnostics (Basel) 2017;7:E10. [PMID: 28212290 DOI: 10.3390/diagnostics7010010] [Cited by in Crossref: 22] [Cited by in F6Publishing: 13] [Article Influence: 5.5] [Reference Citation Analysis]
219 Tinkle CL, Haas-Kogan D. Hepatocellular carcinoma: natural history, current management, and emerging tools. Biologics 2012;6:207-19. [PMID: 22904613 DOI: 10.2147/BTT.S23907] [Cited by in Crossref: 5] [Cited by in F6Publishing: 24] [Article Influence: 0.6] [Reference Citation Analysis]
220 Padia SA, Johnson GE, Yeung RS, Park JO, Hippe DS, Kogut MJ. Irreversible Electroporation in Patients with Hepatocellular Carcinoma: Immediate versus Delayed Findings at MR Imaging. Radiology. 2016;278:285-294. [PMID: 26523493 DOI: 10.1148/radiol.2015150031] [Cited by in Crossref: 30] [Cited by in F6Publishing: 19] [Article Influence: 5.0] [Reference Citation Analysis]
221 Lock M, Malayeri AA, Mian OY, Mayr NA, Herman JM, Lo SS. Computed tomography imaging assessment of postexternal beam radiation changes of the liver. Future Oncol 2016;12:2729-39. [PMID: 27576360 DOI: 10.2217/fon-2016-0165] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 1.2] [Reference Citation Analysis]
222 Bonekamp S, Halappa VG, Geschwind JF, Li Z, Corona-Villalobos CP, Reyes D, Bhagat N, Cosgrove DP, Pawlik TM, Mezey E. Unresectable hepatocellular carcinoma: MR imaging after intraarterial therapy. Part II. Response stratification using volumetric functional criteria after intraarterial therapy. Radiology. 2013;268:431-439. [PMID: 23616632 DOI: 10.1148/radiol.13121637] [Cited by in Crossref: 41] [Cited by in F6Publishing: 36] [Article Influence: 5.1] [Reference Citation Analysis]
223 Jiang T, Zhu AX, Sahani DV. Established and novel imaging biomarkers for assessing response to therapy in hepatocellular carcinoma. J Hepatol. 2013;58:169-177. [PMID: 22944253 DOI: 10.1016/j.jhep.2012.08.022] [Cited by in Crossref: 38] [Cited by in F6Publishing: 30] [Article Influence: 4.2] [Reference Citation Analysis]
224 Sieghart W, Hucke F, Peck-Radosavljevic M. Transarterial chemoembolization: modalities, indication, and patient selection. J Hepatol. 2015;62:1187-1195. [PMID: 25681552 DOI: 10.1016/j.jhep.2015.02.010] [Cited by in Crossref: 118] [Cited by in F6Publishing: 92] [Article Influence: 19.7] [Reference Citation Analysis]
225 Zhu T, Das S, Wong TZ. Integration of PET/MR Hybrid Imaging into Radiation Therapy Treatment. Magn Reson Imaging Clin N Am 2017;25:377-430. [PMID: 28390536 DOI: 10.1016/j.mric.2017.01.001] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
226 Kim CJ, Kim HJ, Park JH, Park DI, Cho YK, Sohn CI, Jeon WK, Kim BI, Kim M. Radiologic response to transcatheter hepatic arterial chemoembolization and clinical outcomes in patients with hepatocellular carcinoma. Liver Int 2014;34:305-12. [DOI: 10.1111/liv.12270] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 2.3] [Reference Citation Analysis]
227 Cervera Deval J. [RECIST and the radiologist]. Radiologia 2014;56:193-205. [PMID: 22902252 DOI: 10.1016/j.rx.2012.03.010] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
228 Vandecaveye V, Michielsen K, De Keyzer F, Laleman W, Komuta M, Op de beeck K, Roskams T, Nevens F, Verslype C, Maleux G. Chemoembolization for hepatocellular carcinoma: 1-month response determined with apparent diffusion coefficient is an independent predictor of outcome. Radiology 2014;270:747-57. [PMID: 24475816 DOI: 10.1148/radiol.13130591] [Cited by in Crossref: 35] [Cited by in F6Publishing: 32] [Article Influence: 4.4] [Reference Citation Analysis]
229 Winters SD, Jackson S, Armstrong GA, Birchall IW, Lee KH, Low G. Value of subtraction MRI in assessing treatment response following image-guided loco-regional therapies for hepatocellular carcinoma. Clin Radiol. 2012;67:649-655. [PMID: 22300821 DOI: 10.1016/j.crad.2011.11.013] [Cited by in Crossref: 24] [Cited by in F6Publishing: 15] [Article Influence: 2.7] [Reference Citation Analysis]
230 Fahrner R, Dondorf F, Ardelt M, Dittmar Y, Settmacher U, Rauchfuß F. Liver transplantation for hepatocellular carcinoma - factors influencing outcome and disease-free survival. World J Gastroenterol 2015;21:12071-82. [PMID: 26576092 DOI: 10.3748/wjg.v21.i42.12071] [Cited by in CrossRef: 10] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
231 Kalb B, Chamsuddin A, Nazzal L, Sharma P, Martin DR. Chemoembolization follow-up of hepatocellular carcinoma with MR imaging: usefulness of evaluating enhancement features on one-month posttherapy MR imaging for predicting residual disease. J Vasc Interv Radiol 2010;21:1396-404. [PMID: 20688534 DOI: 10.1016/j.jvir.2010.05.015] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.7] [Reference Citation Analysis]
232 Sze DY, Iagaru AH, Gambhir SS, De Haan HA, Reid TR. Response to Intra-Arterial Oncolytic Virotherapy with the Herpes Virus NV1020 Evaluated by [ 18 F]Fluorodeoxyglucose Positron Emission Tomography and Computed Tomography. Human Gene Therapy 2012;23:91-7. [DOI: 10.1089/hum.2011.141] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
233 Facciorusso A. Drug-eluting beads transarterial chemoembolization for hepatocellular carcinoma: Current state of the art. World J Gastroenterol 2018;24:161-9. [PMID: 29375202 DOI: 10.3748/wjg.v24.i2.161] [Cited by in CrossRef: 45] [Cited by in F6Publishing: 34] [Article Influence: 15.0] [Reference Citation Analysis]
234 Galizia MS, Töre HG, Chalian H, McCarthy R, Salem R, Yaghmai V. MDCT necrosis quantification in the assessment of hepatocellular carcinoma response to yttrium 90 radioembolization therapy: comparison of two-dimensional and volumetric techniques. Acad Radiol. 2012;19:48-54. [PMID: 22054801 DOI: 10.1016/j.acra.2011.09.005] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 1.9] [Reference Citation Analysis]
235 Tirkes T, Hollar MA, Tann M, Kohli MD, Akisik F, Sandrasegaran K. Response criteria in oncologic imaging: review of traditional and new criteria. Radiographics. 2013;33:1323-1341. [PMID: 24025927 DOI: 10.1148/rg.335125214] [Cited by in Crossref: 153] [Cited by in F6Publishing: 97] [Article Influence: 21.9] [Reference Citation Analysis]
236 Rezai P, Pisaneschi MJ, Feng C, Yaghmai V. A radiologist's guide to treatment response criteria in oncologic imaging: anatomic imaging biomarkers. AJR Am J Roentgenol 2013;201:237-45. [PMID: 23883205 DOI: 10.2214/AJR.12.9862] [Cited by in Crossref: 11] [Cited by in F6Publishing: 4] [Article Influence: 1.4] [Reference Citation Analysis]
237 Kraeber-Bodéré F, Carlier T, Naegelen VM, Shochat E, Lumbroso J, Trampal C, Nagarajah J, Chua S, Hugonnet F, Stokkel M, Gleeson F, Tessier J. Differences in the biologic activity of 2 novel MEK inhibitors revealed by 18F-FDG PET: analysis of imaging data from 2 phase I trials. J Nucl Med 2012;53:1836-46. [PMID: 23143089 DOI: 10.2967/jnumed.112.109421] [Cited by in Crossref: 18] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
238 Abou-Alfa GK. TACE and sorafenib: a good marriage? J Clin Oncol. 2011;29:3949-3952. [PMID: 21911718 DOI: 10.1200/jco.2011.37.9651] [Cited by in Crossref: 43] [Cited by in F6Publishing: 18] [Article Influence: 4.3] [Reference Citation Analysis]
239 Jebar AH, Vile RG, Melcher AA, Griffin S, Selby PJ, Errington-mais F. Progress in clinical oncolytic virus-based therapy for hepatocellular carcinoma. Journal of General Virology 2015;96:1533-50. [DOI: 10.1099/vir.0.000098] [Cited by in Crossref: 17] [Cited by in F6Publishing: 20] [Article Influence: 2.8] [Reference Citation Analysis]
240 Hayano K, Fuentes-Orrego JM, Sahani DV. New approaches for precise response evaluation in hepatocellular carcinoma. World J Gastroenterol 2014;20:3059-68. [PMID: 24696594 DOI: 10.3748/wjg.v20.i12.3059] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
241 Yaghmai V, Miller FH, Rezai P, Benson AB 3rd, Salem R. Response to treatment series: part 2, tumor response assessment--using new and conventional criteria. AJR Am J Roentgenol 2011;197:18-27. [PMID: 21701006 DOI: 10.2214/AJR.11.6581] [Cited by in Crossref: 42] [Cited by in F6Publishing: 19] [Article Influence: 4.2] [Reference Citation Analysis]
242 Monsky WL, Kim I, Loh S, Li CS, Greasby TA, Deutsch LS, Badawi RD. Semiautomated segmentation for volumetric analysis of intratumoral ethiodol uptake and subsequent tumor necrosis after chemoembolization. AJR Am J Roentgenol 2010;195:1220-30. [PMID: 20966331 DOI: 10.2214/AJR.09.3964] [Cited by in Crossref: 41] [Cited by in F6Publishing: 22] [Article Influence: 3.7] [Reference Citation Analysis]
243 Nicolini A, Crespi S, Martinetti L. Drug delivery embolization systems: a physician's perspective. Expert Opin Drug Deliv 2011;8:1071-84. [PMID: 21692688 DOI: 10.1517/17425247.2011.590472] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 1.2] [Reference Citation Analysis]
244 Hinrichs JB, Hasdemir DB, Nordlohne M, Schweitzer N, Wacker F, Vogel A, Kirstein MM, Marquardt S, Rodt T. Health-Related Quality of Life in Patients with Hepatocellular Carcinoma Treated with Initial Transarterial Chemoembolization. Cardiovasc Intervent Radiol 2017;40:1559-66. [PMID: 28488104 DOI: 10.1007/s00270-017-1681-6] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 3.8] [Reference Citation Analysis]
245 Lewandowski RJ, Kulik LM, Riaz A, Senthilnathan S, Mulcahy MF, Ryu RK, Ibrahim SM, Sato KT, Baker T, Miller FH, Omary R, Abecassis M, Salem R. A Comparative Analysis of Transarterial Downstaging for Hepatocellular Carcinoma: Chemoembolization Versus Radioembolization. American Journal of Transplantation 2009;9:1920-8. [DOI: 10.1111/j.1600-6143.2009.02695.x] [Cited by in Crossref: 361] [Cited by in F6Publishing: 281] [Article Influence: 30.1] [Reference Citation Analysis]
246 Spira D, Fenchel M, Lauer UM, Claussen CD, Gregor M, Bitzer M, Horger M. Comparison of different tumor response criteria in patients with hepatocellular carcinoma after systemic therapy with the multikinase inhibitor sorafenib. Acad Radiol 2011;18:89-96. [PMID: 20926315 DOI: 10.1016/j.acra.2010.08.008] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 1.8] [Reference Citation Analysis]
247 Koay EJ, Odisio BC, Javle M, Vauthey JN, Crane CH. Management of unresectable intrahepatic cholangiocarcinoma: how do we decide among the various liver-directed treatments? Hepatobiliary Surg Nutr 2017;6:105-16. [PMID: 28503558 DOI: 10.21037/hbsn.2017.01.16] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 3.5] [Reference Citation Analysis]
248 Shim JH, Han S, Shin YM, Yu E, Park W, Kim KM, Lim YS, Lee HC. Optimal measurement modality and method for evaluation of responses to transarterial chemoembolization of hepatocellular carcinoma based on enhancement criteria. J Vasc Interv Radiol 2013;24:316-25. [PMID: 23312990 DOI: 10.1016/j.jvir.2012.10.022] [Cited by in Crossref: 27] [Cited by in F6Publishing: 21] [Article Influence: 3.4] [Reference Citation Analysis]
249 Bock B, Hasdemir D, Wandrer F, Rodt T, Manns MP, Schulze-Osthoff K, Bantel H. Serum cell death biomarker mirrors liver cancer regression after transarterial chemoembolisation. Aliment Pharmacol Ther 2016;44:747-54. [PMID: 27485159 DOI: 10.1111/apt.13758] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 1.2] [Reference Citation Analysis]
250 Riaz A, Miller FH, Kulik LM, Nikolaidis P, Yaghmai V, Lewandowski RJ, Mulcahy MF, Ryu RK, Sato KT, Gupta R. Imaging response in the primary index lesion and clinical outcomes following transarterial locoregional therapy for hepatocellular carcinoma. JAMA. 2010;303:1062-1069. [PMID: 20233824 DOI: 10.1001/jama.2010.262] [Cited by in Crossref: 140] [Cited by in F6Publishing: 120] [Article Influence: 12.7] [Reference Citation Analysis]
251 Pathak V, Nolte T, Rama E, Rix A, Dadfar SM, Paefgen V, Banala S, Buhl EM, Weiler M, Schulz V, Lammers T, Kiessling F. Molecular magnetic resonance imaging of Alpha-v-Beta-3 integrin expression in tumors with ultrasound microbubbles. Biomaterials 2021;275:120896. [PMID: 34090049 DOI: 10.1016/j.biomaterials.2021.120896] [Reference Citation Analysis]
252 Silva MF, Sherman M. Criteria for liver transplantation for HCC: what should the limits be? J Hepatol 2011;55:1137-47. [PMID: 21718672 DOI: 10.1016/j.jhep.2011.05.012] [Cited by in Crossref: 47] [Cited by in F6Publishing: 43] [Article Influence: 4.7] [Reference Citation Analysis]
253 Gaba RC. Chemoembolization Practice Patterns and Technical Methods Among Interventional Radiologists: Results of an Online Survey. American Journal of Roentgenology 2012;198:692-9. [DOI: 10.2214/ajr.11.7066] [Cited by in Crossref: 50] [Cited by in F6Publishing: 9] [Article Influence: 5.6] [Reference Citation Analysis]
254 Doemel LA, Chapiro J, Laage Gaupp F, Savic LJ, Kucukkaya AS, Petukhova A, Tefera J, Zeevi T, Lin M, Schlachter T, Jaffe A, Strazzabosco M, Patel T, Stein SM. Reliable prediction of survival in advanced-stage hepatocellular carcinoma treated with sorafenib: comparing 1D and 3D quantitative tumor response criteria on MRI. Eur Radiol 2021;31:2737-46. [PMID: 33123796 DOI: 10.1007/s00330-020-07381-9] [Reference Citation Analysis]
255 Gaba RC, Lewandowski RJ, Hickey R, Baerlocher MO, Cohen EI, Dariushnia SR, Janne d'Othée B, Padia SA, Salem R, Wang DS, Nikolic B, Brown DB; Society of Interventional Radiology Technology Assessment Committee. Transcatheter Therapy for Hepatic Malignancy: Standardization of Terminology and Reporting Criteria. J Vasc Interv Radiol 2016;27:457-73. [PMID: 26851158 DOI: 10.1016/j.jvir.2015.12.752] [Cited by in Crossref: 67] [Cited by in F6Publishing: 44] [Article Influence: 13.4] [Reference Citation Analysis]
256 Lee SR, Kilcoyne A, Kambadakone A, Arellano R. Interventional oncology: pictorial review of post-ablation imaging of liver and renal tumors. Abdom Radiol 2016;41:677-705. [DOI: 10.1007/s00261-016-0665-3] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 1.6] [Reference Citation Analysis]
257 Lo EC, N. Rucker A, Federle MP. Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma: Imaging for Diagnosis, Tumor Response to Treatment and Liver Response to Radiation. Seminars in Radiation Oncology 2018;28:267-76. [DOI: 10.1016/j.semradonc.2018.06.010] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 4.7] [Reference Citation Analysis]
258 Xu X, Luo L, Chen J, Wang J, Zhou H, Li M, Jin Z, Chen N, Miao H, Lin M, Dai W, Ahuja AT, Wang YX. Acoustic radiation force impulse elastography for efficacy evaluation after hepatocellular carcinoma radiofrequency ablation: a comparative study with contrast-enhanced ultrasound. Biomed Res Int 2014;2014:901642. [PMID: 24895624 DOI: 10.1155/2014/901642] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
259 Riaz A, Ryu RK, Kulik LM, Mulcahy MF, Lewandowski RJ, Minocha J, Ibrahim SM, Sato KT, Baker T, Miller FH. Alpha-fetoprotein response after locoregional therapy for hepatocellular carcinoma: oncologic marker of radiologic response, progression, and survival. J Clin Oncol. 2009;27:5734-5742. [PMID: 19805671 DOI: 10.1200/jco.2009.23.1282] [Cited by in Crossref: 155] [Cited by in F6Publishing: 67] [Article Influence: 12.9] [Reference Citation Analysis]
260 Camacho JC, Kokabi N, Xing M, Prajapati HJ, El-Rayes B, Kim HS. Modified response evaluation criteria in solid tumors and European Association for The Study of the Liver criteria using delayed-phase imaging at an early time point predict survival in patients with unresectable intrahepatic cholangiocarcinoma following yttrium-90 radioembolization. J Vasc Interv Radiol. 2014;25:256-265. [PMID: 24461131 DOI: 10.1016/j.jvir.2013.10.056] [Cited by in Crossref: 58] [Cited by in F6Publishing: 52] [Article Influence: 8.3] [Reference Citation Analysis]
261 Llovet JM, Lencioni R. mRECIST for HCC: Performance and novel refinements. J Hepatol. 2020;72:288-306. [PMID: 31954493 DOI: 10.1016/j.jhep.2019.09.026] [Cited by in Crossref: 48] [Cited by in F6Publishing: 40] [Article Influence: 48.0] [Reference Citation Analysis]
262 Takayasu K. Transarterial chemoembolization for hepatocellular carcinoma over three decades: current progress and perspective. Jpn J Clin Oncol. 2012;42:247-255. [PMID: 22407946 DOI: 10.1093/jjco/hys020] [Cited by in Crossref: 27] [Cited by in F6Publishing: 29] [Article Influence: 3.0] [Reference Citation Analysis]
263 Louis C, Dewas S, Mirabel X, Lacornerie T, Adenis A, Bonodeau F, Lartigau E. Stereotactic radiotherapy of hepatocellular carcinoma: preliminary results. Technol Cancer Res Treat. 2010;9:479-487. [PMID: 20815419 DOI: 10.1177/153303461000900506] [Cited by in Crossref: 86] [Cited by in F6Publishing: 69] [Article Influence: 7.8] [Reference Citation Analysis]
264 Memon K, Kulik L, Lewandowski RJ, Gupta R, Ryu RK, Miller FH, Vouche M, Atassi R, Ganger D, Mulcahy MF, Salem R. Prospective Evaluation of Patients with Early-/Intermediate-stage Hepatocellular Carcinoma with Disease Progression Following Arterial Locoregional Therapy: Candidacy for Systemic Treatment or Clinical Trials. Journal of Vascular and Interventional Radiology 2013;24:1189-1197.e2. [DOI: 10.1016/j.jvir.2012.12.025] [Cited by in Crossref: 14] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
265 Bonekamp D, Bonekamp S, Halappa VG, Geschwind JF, Eng J, Corona-Villalobos CP, Pawlik TM, Kamel IR. Interobserver agreement of semi-automated and manual measurements of functional MRI metrics of treatment response in hepatocellular carcinoma. Eur J Radiol. 2014;83:487-496. [PMID: 24387824 DOI: 10.1016/j.ejrad.2013.11.016] [Cited by in Crossref: 50] [Cited by in F6Publishing: 31] [Article Influence: 6.3] [Reference Citation Analysis]
266 Mirdad RS, Madison Hyer J, Diaz A, Tsilimigras DI, Azap RA, Paro A, Pawlik TM. Postoperative imaging surveillance for hepatocellular carcinoma: How much is enough? J Surg Oncol 2021;123:1568-77. [PMID: 33596330 DOI: 10.1002/jso.26433] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
267 Vogl TJ, Hagar A, Nour-eldin NA, Gruber-rouh T, Eichler K, Ackermann H, Bechstein WO, Naguib NNN. High-frequency versus low-frequency microwave ablation in malignant liver tumours: evaluation of local tumour control and survival. International Journal of Hyperthermia 2016;32:868-75. [DOI: 10.1080/02656736.2016.1212107] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]